Tokushima University / Educator and Researcher Directory --- Abe, Shinji

Personal Web Page

https://researchmap.jp/ashinji (researchmap)

Field of Study

○	Pharmacy

Subject of Study

○

Book / Paper

Book:

1.	Kirino Yutaka, Koichiro Tsuchiya, Youichi Sato, Shinji Abe and Chiemi Sato : 世界薬学探訪記四国の全薬学部による海外薬学視察団最新報告: 日本の薬学，薬剤師はどう変わるべきか?, Apr. 2019.
2.	Kazuyoshi Kawazoe and Shinji Abe : 第8章静脈栄養 A.(4) 症例と解説, Medical Review Co.,Ltd, Osaka, Jan. 2011.
3.	木宿昌俊, 森剛志, 田島壮一郎, 板東篤史, Shinji Abe, Kazuyoshi Kawazoe and Kazuo Minakuchi : 最近の文献情報より新しいがん治療に向けて(2), The Japanese Society of Hospital Pharmacists, Tokyo, Jul. 2007.
4.	小笠原聡子, 桐野靖, 米田良子, 元林有紀, 伊勢夏子, Shinji Abe, Kazuyoshi Kawazoe and Kazuo Minakuchi : 最近の文献情報より脳・精神疾患の最前線(2), The Japanese Society of Hospital Pharmacists, Tokyo, May 2007.
5.	中村敏己, 山下祐紀雄, 西迫寛隆, 下岡幸恵, 西谷典子, Shinji Abe, Kazuyoshi Kawazoe and Kazuo Minakuchi : 最近の文献情報より新しいがん治療に向けて(1), The Japanese Society of Hospital Pharmacists, Tokyo, Mar. 2007.
6.	Shinji Abe, 塩田直青子, 田中裕子, 廣永有沙, 道倉亜実, Kazuyoshi Kawazoe and Kazuo Minakuchi : 最近の文献情報より脳・精神疾患の最前線(1), The Japanese Society of Hospital Pharmacists, Tokyo, Jan. 2007.

Academic Paper (Judged Full Paper):

1.	Kei Kawada, Tomoaki Ishida, Hitoshi Fukuda, Yuki Hyohdoh, Toru Kubo, Tomoyuki Hamada, Yuichi Baba, Toshinobu Hayashi, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda, Hiroaki Kitaoka and Keisuke Ishizawa : Effects of renin-angiotensin system inhibitor and beta-blocker use on mortality in older patients with heart failure with reduced ejection fraction in Japan., Frontiers in Cardiovascular Medicine, Vol.11, 2024. (Summary) RAS inhibitors prevented all-cause mortality and cardiac death at all ages, whereas beta-blockers had different effects depending on the patient's age. This study suggested that the choice of beta-blockers and RAS inhibitors is more important in older patients with HFrEF than in younger patients with the same condition. (Link to Publication Site) ● Publication site (DOI): 10.3389/fcvm.2024.1377228 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38883984 ● Search Scopus @ Elsevier (PMID): 38883984 ● Search Scopus @ Elsevier (DOI): 10.3389/fcvm.2024.1377228 (DOI: 10.3389/fcvm.2024.1377228, PubMed: 38883984)
2.	Kei Kawada, Tomoaki Ishida, Shumpei Morisawa, Kohei Jobu, Youichirou Higashi, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda, Mitsuhiko Miyamura and Keisuke Ishizawa : Atractylodes lancea (Thunb.) DC. [Asteraceae] rhizome-derived exosome-like nanoparticles suppress lipopolysaccharide-induced inflammation in murine microglial cells., Frontiers in Pharmacology, Vol.15, 2024. (Summary) Exosome-like nanoparticles (ELNs) mediate interspecies intercellular communications and modulate gene expression. In this study, we isolated and purified ELNs from the dried rhizome of Atractylodes lancea (Thunb.) DC. [Asteraceae] (ALR-ELNs), a traditional natural medicine, and investigated their potential as neuroinflammatory therapeutic agents. ALR-ELN samples were isolated and purified using differential centrifugation, and their physical features and microRNA contents were analyzed through transmission electron microscopy and RNA sequencing, respectively. BV-2 microglial murine cells and primary mouse microglial cells were cultured , and their ability to uptake ALR-ELNs was explored using fluorescence microscopy. The capacity of ALR-ELNs to modulate the anti-inflammatory responses of these cells to lipopolysaccharide (LPS) exposure was assessed through mRNA and protein expression analyses. Overall, BV-2 cells were found to internalize ALR-ELNs, which comprised three microRNAs (ath-miR166f, ath-miR162a-5p, and ath-miR162b-5p) that could have anti-inflammatory activity. Pretreatment of BV-2 cells with ALR-ELN prevented the pro-inflammatory effects of LPS stimulation by significantly reducing the levels of nitric oxide, interleukin-1β, interleukin-6, and tumor necrosis factor-α. Notably, the mRNA levels of , and in BV-2 cells, which increased upon LPS exposure, were significantly reduced following ALR-ELN treatment. Moreover, the mRNA levels of heme oxygenase 1, , and also increased significantly following ALR-ELN treatment. In addition, pretreatment of primary mouse microglial cells with ALR-ELN prevented the pro-inflammatory effects of LPS stimulation by significantly reducing the levels of nitric oxide. Our findings indicate that ALR-ELNs exhibit anti-inflammatory effects on murine microglial cells. Further validation may prove ALR-ELNs as a promising neuroinflammatory therapeutic agent. (Link to Publication Site) ● Publication site (DOI): 10.3389/fphar.2024.1302055 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38738173 ● Search Scopus @ Elsevier (PMID): 38738173 ● Search Scopus @ Elsevier (DOI): 10.3389/fphar.2024.1302055 (DOI: 10.3389/fphar.2024.1302055, PubMed: 38738173)
3.	Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Thi Na Nguyen, Hiroshi Nokihara, Seidai Satou, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, K Mika Kaneko, Yukinari Kato and Yasuhiko Nishioka : Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells., Cancer Science, Vol.115, No.2, 357-368, 2024. (Summary) -f enhanced the antitumor effects of CTLA-4 blockade. Combination therapy with anti-PDPN Ab and anti-CTLA-4 Ab increased tumor-infiltrating natural killer (NK) cells. The depletion of NK cells inhibited the synergistic effects of PMab-1-mG (Keyword) Rats / Mice / Animals / Cricetinae / Mesothelioma, Malignant / Antibodies, Monoclonal / CTLA-4 Antigen / Membrane Glycoproteins / Mesothelioma / Killer Cells, Natural / Cricetulus / CHO Cells (Tokushima University Institutional Repository) ● Metadata: 119228 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.16046 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38148492 ● Search Scopus @ Elsevier (PMID): 38148492 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.16046 (Tokushima University Institutional Repository: 119228, DOI: 10.1111/cas.16046, PubMed: 38148492)
4.	Chiemi Sato, Koichiro Tsuchiya and Shinji Abe : Evaluation of the Influence of Non-face-to-face Teaching in Case Study Exercise Module Education Outcome Evaluation using a Rubric for Comprehension of Clinical Laboratory Data, Journal of University Education Research, No.20, 45-51, 2023. (Summary) 2020年，新型コロナウイルス感染症(COVID-19)拡大により，大学では対面授業に替わる新たな授業形態が必要となった．本学でも，臨床実習後に行う模擬症例演習科目で非対面授業を取り入れた．そこで本研究では，この非対面授業の教育成果を確認するため，従来の対面授業との比較を行った．臨床検査値に対する学生の理解度を指標とした考察の結果，非対面授業においても教育成果は得られていたものの，対面授業と比べると十分とは言えないことが示唆された．要因の一つとして，今回行った非対面授業はグループ討論を含まなかったため，学生間で知識や意見交換ができなかったことが考えられる．様々な授業形態が可能となった時代を迎え，今後も教育成果の評価とそれに基づく授業改善を継続して行い，それぞれの利点を活かした教育プログラムを開発していく必要がある． (Keyword) 薬学教育 / 非対面授業 / 授業評価 / 臨床検査値 / pharmacy education / non-face-to-face teaching / education outcome evaluation / clinical laboratory data (Tokushima University Institutional Repository) ● Metadata: 118124 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050577199130987648 (Tokushima University Institutional Repository: 118124, CiNii: 1050577199130987648)
5.	Chiemi Sato and Shinji Abe : Development of an Education System to Foster Pharmacy Students Ability to Think Independently and Proactively, Journal of University Education Research, No.19, 62-70, 2022. (Summary) 主体的な学びが注目される近年，薬剤師教育においても学生の主体性育成は必須である．こうした背景から，徳島大学薬学部では2015 年度以降の薬局実務実習において，学生自身が課題を発見・解決した記録を実習レポートのひとつとして導入している．そこで本研究では，学生の主体的な学習姿勢に対する本取り組みの影響を評価するため，導入前(2013 年度)と導入後(2015 ~ 2018 年度)の学習姿勢に関する自己評価アンケートを分析した．本取り組み導入後，「自主性・積極性」，「考察力」，「観察力・体得努力」に高い成長を感じた学生が増加しており，本取り組みは，学生の主体的な学習姿勢の醸成に寄与することが示唆された． (Keyword) 薬学教育 / 実務実習 / 主体性育成 / モデル・コアカリキュラム / pharmaceutical education system / practical training / proactive attitude / model core curriculum (Tokushima University Institutional Repository) ● Metadata: 116855 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050573243703332992 (Tokushima University Institutional Repository: 116855, CiNii: 1050573243703332992)
6.	Yuki Tsuchihashi, Shinji Abe, Licht Miyamoto, Honoka Tsunematsu, Toshihiro Izumi, Aya Hatano, Hiroko Okuno, Megumi Yamane, Takashi Yasuoka, Yasumasa Ikeda and Koichiro Tsuchiya : Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer., Molecular Pharmaceutics, Vol.17, No.4, 1049-1058, 2020. (Summary) Camptothecin possesses broad antitumor spectra on various cancers. In spite of its marked tumor-suppressing potency, camptothecin is too hydrophobic to be solved in water and therefore not currently in clinical use. CPT-11 (irinotecan) is one of the hydrophilic analogues of camptothecin and widely prescribed. However, its water solubility is still low and furthermore evokes severe diarrhea. Therefore, we designed and synthesized novel highly hydrophilic camptothecin derivatives by conjugating SN38 with branched glycerol trimer (SN38-BGL), which we have been developing as a unique strategy to endow hydrophobic molecule with much hydrophilicity, to maximize the benefit of CPT-11 and minimize the adverse effects. The SN38-BGLs exhibited equivalent or slightly stronger tumor-suppressing effects in murine xenograft human lung cancer models compared to CPT-11. However, neither early- nor late-onset diarrhea was observed when SN38-BGL was administered. Heights of villi in jejunum and ileum were bigger than those from CPT-11-treated mice, indicating that SN38-BGL is less harmful than CPT-11. Ex vivo digestion by liver microsome did not yield SN38 but a couple of other molecules against our expectations, which suggests the involvement of other active metabolites than SN38 and may explain the differences. Hence, SN38-BGLs can be a novel hydrophilic camptothecin derivative without causing severe diarrhea. (Keyword) A549 Cells / Animals / Antineoplastic Agents, Phytogenic / Camptothecin / Cell Line, Tumor / Diarrhea / Disease Models, Animal / Glycerol / Heterografts / Humans / Hydrophobic and Hydrophilic Interactions / Irinotecan / Lung Neoplasms / Male / Mice / Mice, Inbred BALB C / Mice, Nude / Microsomes, Liver / Rats, Sprague-Dawley / Xenograft Model Antitumor Assays (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.molpharmaceut.9b00249 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32068412 ● Search Scopus @ Elsevier (PMID): 32068412 ● Search Scopus @ Elsevier (DOI): 10.1021/acs.molpharmaceut.9b00249 (DOI: 10.1021/acs.molpharmaceut.9b00249, PubMed: 32068412)
7.	Shunsuke Itai, Tomokazu Ohishi, K Mika Kaneko, Shinji Yamada, Shinji Abe, Takuro Nakamura, Miyuki Yanaka, Yao-Wen Chang, Shun-Ichi Ohba, Yasuhiko Nishioka, Manabu Kawada, Hiroyuki Harada and Yukinari Kato : Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma., Oncotarget, Vol.9, No.32, 22480-22497, 2018. (Summary) These results suggested that a core fucose-deficient anti-PODXL mAb could be useful for antibody-based therapy against PODXL-expressing OSCCs. (Tokushima University Institutional Repository) ● Metadata: 113062 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.25132 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29854293 ● Search Scopus @ Elsevier (PMID): 29854293 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.25132 (Tokushima University Institutional Repository: 113062, DOI: 10.18632/oncotarget.25132, PubMed: 29854293)
8.	Mika K Kaneko, Akiko Kunita, Shinji Yamada, Takuro Nakamura, Miyuki Yanaka, Noriko Saidoh, Yao-Wen Chang, Saori Handa, Satoshi Ogasawara, Tomokazu Ohishi, Shinji Abe, Shunsuke Itai, Hiroyuki Harada, Manabu Kawada, Yasuhiko Nishioka, Masashi Fukayama and Yukinari Kato : Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas., Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol.36, No.4, 157-162, 2017. (Link to Publication Site) ● Publication site (DOI): 10.1089/mab.2017.0020 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28665782 ● Search Scopus @ Elsevier (PMID): 28665782 ● Search Scopus @ Elsevier (DOI): 10.1089/mab.2017.0020 (DOI: 10.1089/mab.2017.0020, PubMed: 28665782)
9.	Naoto Okada, Shinya Kobayashi, Kouta Moriyama, Kohsuke Miyataka, Shinji Abe, Chiemi Sato and Kazuyoshi Kawazoe : Helianthus tuberosus (Jerusalem artichoke) tubers improve glucose tolerance and hepatic lipid profile in rats fed a high-fat diet., Asian Pacific Journal of Tropical Medicine, Vol.10, No.5, 439-443, 2017. (Tokushima University Institutional Repository) ● Metadata: 114999 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.apjtm.2017.03.028 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28647180 ● Search Scopus @ Elsevier (PMID): 28647180 ● Search Scopus @ Elsevier (DOI): 10.1016/j.apjtm.2017.03.028 (Tokushima University Institutional Repository: 114999, DOI: 10.1016/j.apjtm.2017.03.028, PubMed: 28647180)
10.	K Mika Kaneko, Takuro Nakamura, Akiko Kunita, Masashi Fukayama, Shinji Abe, Yasuhiko Nishioka, Shinji Yamada, Miyuki Yanaka, Noriko Saidoh, Kanae Yoshida, Yuki Fujii, Satoshi Ogasawara and Yukinari Kato : ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity., Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol.36, No.3, 104-112, 2017. (Link to Publication Site) ● Publication site (DOI): 10.1089/mab.2017.0014 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28504613 ● Search Scopus @ Elsevier (PMID): 28504613 ● Search Scopus @ Elsevier (DOI): 10.1089/mab.2017.0014 (DOI: 10.1089/mab.2017.0014, PubMed: 28504613)
11.	Mika K Kaneko, Shinji Yamada, Takuro Nakamura, Shinji Abe, Yasuhiko Nishioka, Akiko Kunita, Masashi Fukayama, Yuki Fujii, Satoshi Ogasawara and Yukinari Kato : Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity., Cancer Medicine, Vol.6, No.4, 768-777, 2017. (Summary) Human podoplanin (hPDPN), a platelet aggregation-inducing transmembrane glycoprotein, is expressed in different types of tumors, and it binds to C-type lectin-like receptor 2 (CLEC-2). The overexpression of hPDPN is involved in invasion and metastasis. Anti-hPDPN monoclonal antibodies (mAbs) such as NZ-1 have shown antitumor and antimetastatic activities by binding to the platelet aggregation-stimulating (PLAG) domain of hPDPN. Recently, we developed a novel mouse anti-hPDPN mAb, LpMab-2, using the cancer-specific mAb (CasMab) technology. In this study we developed chLpMab-2, a human-mouse chimeric anti-hPDPN antibody, derived from LpMab-2. chLpMab-2 was produced using fucosyltransferase 8-knockout (KO) Chinese hamster ovary (CHO)-S cell lines. By flow cytometry, chLpMab-2 reacted with hPDPN-expressing cancer cell lines including glioblastomas, mesotheliomas, and lung cancers. However, it showed low reaction with normal cell lines such as lymphatic endothelial and renal epithelial cells. Moreover, chLpMab-2 exhibited high antibody-dependent cellular cytotoxicity (ADCC) against PDPN-expressing cells, despite its low complement-dependent cytotoxicity. Furthermore, treatment with chLpMab-2 abolished tumor growth in xenograft models of CHO/hPDPN, indicating that chLpMab-2 suppressed tumor development via ADCC. In conclusion, chLpMab-2 could be useful as a novel antibody-based therapy against hPDPN-expressing tumors. (Tokushima University Institutional Repository) ● Metadata: 115039 (Link to Publication Site) ● Publication site (DOI): 10.1002/cam4.1049 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28332312 ● Search Scopus @ Elsevier (PMID): 28332312 ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.1049 (Tokushima University Institutional Repository: 115039, DOI: 10.1002/cam4.1049, PubMed: 28332312)
12.	Mika K Kaneko, Shinji Abe, Satoshi Ogasawara, Yuki Fujii, Shinji Yamada, Takeshi Murata, Hiroaki Uchida, Hideaki Tahara, Yasuhiko Nishioka and Yukinari Kato : Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain., Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol.36, No.1, 25-29, 2017. (Link to Publication Site) ● Publication site (DOI): 10.1089/mab.2016.0047 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28157429 ● Search Scopus @ Elsevier (PMID): 28157429 ● Search Scopus @ Elsevier (DOI): 10.1089/mab.2016.0047 (DOI: 10.1089/mab.2016.0047, PubMed: 28157429)
13.	Yukinari Kato, Akiko Kunita, Masashi Fukayama, Shinji Abe, Yasuhiko Nishioka, Hiroaki Uchida, Hideaki Tahara, Shinji Yamada, Miyuki Yanaka, Takuro Nakamura, Noriko Saidoh, Kanae Yoshida, Yuki Fujii, Ryusuke Honma, Michiaki Takagi, Satoshi Ogasawara, Takeshi Murata and K Mika Kaneko : Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity., Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol.36, No.1, 20-24, 2017. (Link to Publication Site) ● Publication site (DOI): 10.1089/mab.2016.0045 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28234556 ● Search Scopus @ Elsevier (PMID): 28234556 ● Search Scopus @ Elsevier (DOI): 10.1089/mab.2016.0045 (DOI: 10.1089/mab.2016.0045, PubMed: 28234556)
14.	Mika K Kaneko, Takuro Nakamura, Ryusuke Honma, Satoshi Ogasawara, Yuki Fujii, Shinji Abe, Michiaki Takagi, Hiroyuki Harada, Hiroyoshi Suzuki, Yasuhiko Nishioka and Yukinari Kato : Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN., Cancer Medicine, Vol.6, No.2, 382-396, 2017. (Summary) Human podoplanin (hPDPN), which binds to C-type lectin-like receptor-2 (CLEC-2), is involved in platelet aggregation and cancer metastasis. The expression of hPDPN in cancer cells or cancer-associated fibroblasts indicates poor prognosis. Human lymphatic endothelial cells, lung-type I alveolar cells, and renal glomerular epithelial cells express hPDPN. Although numerous monoclonal antibodies (mAbs) against hPDPN are available, they recognize peptide epitopes of hPDPN. Here, we generated a novel anti-hPDPN mAb, LpMab-21. To characterize the hPDPN epitope recognized by the LpMab-21, we established glycan-deficient CHO-S and HEK-293T cell lines, using the CRISPR/Cas9 or TALEN. Flow cytometric analysis revealed that the minimum hPDPN epitope, in which sialic acid is linked to Thr76, recognized by LpMab-21 is Thr76-Arg79. LpMab-21 detected hPDPN expression in glioblastoma, oral squamous carcinoma, and seminoma cells as well as in normal lymphatic endothelial cells. However, LpMab-21 did not react with renal glomerular epithelial cells or lung type I alveolar cells, indicating that sialylation of hPDPN Thr76 is cell-type-specific. LpMab-21 combined with other anti-hPDPN antibodies that recognize different epitopes may therefore be useful for determining the physiological function of sialylated hPDPN. (Tokushima University Institutional Repository) ● Metadata: 115040 (Link to Publication Site) ● Publication site (DOI): 10.1002/cam4.954 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28101903 ● Search Scopus @ Elsevier (PMID): 28101903 ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.954 (Tokushima University Institutional Repository: 115040, DOI: 10.1002/cam4.954, PubMed: 28101903)
15.	Shinji Abe, Kato Mika Kaneko, Yuki Tsuchihashi, Toshihiro Izumi, Satoshi Ogasawara, Naoto Okada, Chiemi Sato, Makoto Tobiume, Kenji Otsuka, Licht Miyamoto, Koichiro Tsuchiya, Kazuyoshi Kawazoe, Yukinari Kato and Yasuhiko Nishioka : Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model., Cancer Science, Vol.107, No.9, 1198-1205, 2016. (Keyword) cancer immunotherapy / ADCC / podoplanin (Tokushima University Institutional Repository) ● Metadata: 112378 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.12985 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27294401 ● Search Scopus @ Elsevier (PMID): 27294401 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.12985 (Tokushima University Institutional Repository: 112378, DOI: 10.1111/cas.12985, PubMed: 27294401)
16.	Naoto Okada, Takeshi Hanafusa, Shinji Abe, Chiemi Sato, Toshimi Nakamura, Kazuhiko Teraoka, Masahiro Abe, Kazuyoshi Kawazoe and Keisuke Ishizawa : Evaluation of the risk factors associated with high-dose chemotherapyinduced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: Possible usefulness of cryotherapy in dysgeusia prevention, Supportive Care in Cancer, Vol.24, No.9, 3979-3985, 2016. (Summary) Dysgeusia is one of the sporadic adverse effects induced by chemotherapy, but it remains poorly understood. The aim of this study was to retrospectively identify the risk factors related with dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation (AHSCT). Forty-eight patients with myeloma or lymphoma undergoing AHSCT were enrolled in this study. Data regarding dysgeusia and symptoms were collected by interviews conducted by medical workers. Patient characteristics and unfavorable effects induced by dysgeusia were obtained from medical records and analyzed. Logistic regression analysis was performed to identify the risk factors related with dysgeusia. Of the 48 patients, 20 (42 %) had dysgeusia after AHSCT. The total period of parenteral nutrition (TPN) administration and period of decreased oral intake in the dysgeusia group were statistically longer than those in the non-dysgeusia group. Multivariate analyses revealed that oral mucositis (odds ratio: 30.3; p < 0.01) and the type of chemotherapy prior to AHSCT (odds ratio: 6.56; p < 0.05) were independent risk factors, while oral cryotherapy was the independent suppressive factor of dysgeusia (odds ratio: 0.14; p < 0.05). Our study showed that dysgeusia after AHSCT led to the decrease in oral intake and extended the TPN administration period. Moreover, MEAM or LEED chemotherapy and oral mucositis were independent risk factors for dysgeusia in patients undergoing AHSCT, while oral cryotherapy was an independent suppressive factor for dysgeusia. Therefore, oral cryotherapy should be implemented into the regimen of supportive care management in patients undergoing AHSCT. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00520-016-3244-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27129837 ● Search Scopus @ Elsevier (PMID): 27129837 ● Search Scopus @ Elsevier (DOI): 10.1007/s00520-016-3244-9 (DOI: 10.1007/s00520-016-3244-9, PubMed: 27129837)
17.	Yukinari Kato, Akiko Kunita, Shinji Abe, Satoshi Ogasawara, Yuki Fujii, Hiroharu Oki, Masashi Fukayama, Yasuhiko Nishioka and Mika K. Kaneko : The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity, Oncotarget, Vol.6, No.34, 36003-36018, 2015. (Summary) Podoplanin (PDPN/Aggrus/T1α) binds to C-type lectin-like receptor-2 (CLEC-2) and induces platelet aggregation. PDPN is associated with malignant progression, tumor metastasis, and poor prognosis in several types of cancer. Although many anti-human PDPN (hPDPN) monoclonal antibodies (mAbs), such as D2-40 and NZ-1, have been established, these epitopes are limited to the platelet aggregation-stimulating (PLAG) domain (amino acids 29-54) of hPDPN. Recently, we developed a novel mouse anti-hPDPN mAb, LpMab-7, which is more sensitive than D2-40 and NZ-1, using the Cancer-specific mAb (CasMab) method. The epitope of LpMab-7 was shown to be entirely different from that of NZ-1, a neutralizing mAb against the PLAG domain according to an inhibition assay and lectin microarray analysis. In the present study, we produced a mouse-human chimeric anti-hPDPN mAb, chLpMab-7. ChLpMab-7 showed high antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Furthermore, chLpMab-7 inhibited the growth of hPDPN-expressing tumors in vivo. Although chLpMab-7 recognizes a non-PLAG domain of hPDPN, it suppressed the hematogenous metastasis of hPDPN-expressing tumors. These results indicated that chLpMab-7 suppressed tumor development and hematogenous metastasis in a neutralization-independent manner. In conclusion, hPDPN shows promise as a target in the development of a novel antibody-based therapy. (Tokushima University Institutional Repository) ● Metadata: 115672 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.5339 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26416352 ● Summary page in Scopus @ Elsevier: 2-s2.0-84945548818 (Tokushima University Institutional Repository: 115672, DOI: 10.18632/oncotarget.5339, PubMed: 26416352, Elsevier: Scopus)
18.	Shinji Abe, Yuki Morita, Mika Kato Kaneko, Masaki Hanibuchi, Yuta Tsujimoto, Hisatsugu Goto, Souji Kakiuchi, Yoshinori Aono, Jun Huang, Seidai Sato, Masatoshi Kishuku, Yuki Taniguchi, Mami Azuma, Kazuyoshi Kawazoe, Yoshitaka Sekido, Seiji Yano, Shin-ichi Akiyama, Saburo Sone, Kazuo Minakuchi, Yukinari Kato and Yasuhiko Nishioka : A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody, The Journal of Immunology, Vol.190, No.12, 6239-6249, 2013. (Summary) Podoplanin (Aggrus), which is a type I transmembrane sialomucin-like glycoprotein, is highly expressed in malignant pleural mesothelioma (MPM). We previously reported the generation of a rat anti-human podoplanin Ab, NZ-1, which inhibited podoplanin-induced platelet aggregation and hematogenous metastasis. In this study, we examined the antitumor effector functions of NZ-1 and NZ-8, a novel rat-human chimeric Ab generated from NZ-1 including Ab-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against MPM in vitro and in vivo. Immunostaining with NZ-1 showed the expression of podoplanin in 73% (11 out of 15) of MPM cell lines and 92% (33 out of 36) of malignant mesothelioma tissues. NZ-1 could induce potent ADCC against podoplanin-positive MPM cells mediated by rat NK (CD161a(+)) cells, but not murine splenocytes or human mononuclear cells. Treatment with NZ-1 significantly reduced the growth of s.c. established tumors of MPM cells (ACC-MESO-4 or podoplanin-transfected MSTO-211H) in SCID mice, only when NZ-1 was administered with rat NK cells. In in vivo imaging, NZ-1 efficiently accumulated to xenograft of MPM, and its accumulation continued for 3 wk after systemic administration. Furthermore, NZ-8 preferentially recognized podoplanin expressing in MPM, but not in normal tissues. NZ-8 could induce higher ADCC mediated by human NK cells and complement-dependent cytotoxicity as compared with NZ-1. Treatment with NZ-8 and human NK cells significantly inhibited the growth of MPM cells in vivo. These results strongly suggest that targeting therapy to podoplanin with therapeutic Abs (i.e., NZ-8) derived from NZ-1 might be useful as a novel immunotherapy against MPM. (Keyword) Animals / Antibodies, Monoclonal / Flow Cytometry / Humans / Immunohistochemistry / Immunotherapy / Male / Membrane Glycoproteins / Mesothelioma / Mice / Mice, SCID / Pleural Neoplasms / Rats / Rats, Wistar / Recombinant Fusion Proteins / Xenograft Model Antitumor Assays (Link to Publication Site) ● Publication site (DOI): 10.4049/jimmunol.1300448 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23690472 ● Search Scopus @ Elsevier (PMID): 23690472 ● Search Scopus @ Elsevier (DOI): 10.4049/jimmunol.1300448 (DOI: 10.4049/jimmunol.1300448, PubMed: 23690472)
19.	Licht Miyamoto, Masashi Watanabe, Chiaki Taoka, Mai Kono, Yosuke Tomida, Tsuyoshi Matsushita, Masaki Kamiya, Hatsuhiko Hattori, Keisuke Ishizawa, Shinji Abe, Hisao Nemoto and Koichiro Tsuchiya : A novel prodrug strategy for extremely hydrophobic agents; - Conjugation to symmetrically branched glycerol trimer improves pharmacological and pharmacokinetic properties of fenofibrate, Molecular Pharmaceutics, Vol.10, No.7, 2723-2729, 2013. (Summary) Management of a lipophilic-hydrophilic balance is a key element in drug design to achieve desirable pharmacokinetic characters. Therefore we have created unique modular molecules, symmetrically branched oligoglycerols (BGL), as an alternative way to endow hydrophobic molecules with sufficient hydrophilicity. We have successfully demonstrated amelioration of the water solubility and thermal stability of several hydrophobic agents by covalent conjugation to BGL so far. However, it has not been clarified whether the molecular modification by BGL also improves the pharmacological and/or pharmacokinetic properties indeed. Recently, we synthesized a novel BGL-prodrug derivative of fenofibrate, which is an antihyperlipidemic agent and one of the most hydrophobic medicinal compounds currently used clinically, by conjugating fenofibric acid to symmetrically branched glycerol trimer (BGL003), the simplest BGL. We have previously demonstrated that the hydrophilicity and water solubility of fenofibrate are improved more than 2000 times just by conjugation to the BGL003. To verify our hypothesis that the prodrug strategy with BGL should improve pharmacological efficacy and pharmacokinetic properties of extremely hydrophobic agents such as fenofibrate by the rise in hydrophilicity, we evaluated the BGL003-prodrug derivative of fenofibrate (FF-BGL) using rodent models. Here we demonstrate that the lipid-lowering effects of fenofibrate are much potentiated by chemical conjugation to BGL003 without exhibiting significant toxicity. Plasma concentration of fenofibric acid, an active metabolite of fenofibrate, after single oral administration of FF-BGL was more than 3 times higher than that of fenofibrate, in accordance. In fasting rats, plasma concentration of fenofibric acid after fenofibrate administration was curtailed into less than half of that in ad libitum-fed rats, while FF-BGL showed about the same plasma level even in the starving rats. This is the first report showing that BGL-prodrug improves pharmacological and pharmacokinetic properties as well as hydrophilicity of highly hydrophobic compounds. Furthermore, prodrug strategy using BGL suggests the possibility of diminishing the food-drug interaction effects, which should be advantageous for promoting drug compliance. BGL will be a suitable prodrug strategy to ameliorate physical, pharmacological, and pharmacokinetic characteristics of extremely hydrophobic compounds. (Link to Publication Site) ● Publication site (DOI): 10.1021/mp400133j (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23672178 ● Search Scopus @ Elsevier (PMID): 23672178 ● Search Scopus @ Elsevier (DOI): 10.1021/mp400133j (DOI: 10.1021/mp400133j, PubMed: 23672178)
20.	Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Shinji Abe, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, G Julie Ledford, Saburo Sone and Yasuhiko Nishioka : Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages., The American Journal of Pathology, Vol.182, No.5, 1843-1853, 2013. (Summary) Surfactant protein A (SP-A) is a large multimeric protein found in the lungs. In addition to its immunoregulatory function in infectious respiratory diseases, SP-A is also used as a marker of lung adenocarcinoma. Despite the finding that SP-A expression levels in cancer cells has a relationship with patient prognosis, the function of SP-A in lung cancer progression is unknown. We investigated the role of SP-A in lung cancer progression by introducing the SP-A gene into human lung adenocarcinoma cell lines. SP-A gene transduction suppressed the progression of tumor in subcutaneous xenograft or lung metastasis mouse models. Immunohistochemical analysis showed that the number of M1 antitumor tumor-associated macrophages (TAMs) was increased and the number of M2 tumor-promoting TAMs was not changed in the tumor tissue produced by SP-A-expressing cells. In addition, natural killer (NK) cells were also increased and activated in the SP-A-expressing tumor. Moreover, SP-A did not inhibit tumor progression in mice depleted of NK cells. Taking into account that SP-A did not directly activate NK cells, these results suggest that SP-A inhibited lung cancer progression by recruiting and activating NK cells via controlling the polarization of TAMs. (Tokushima University Institutional Repository) ● Metadata: 106071 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ajpath.2013.01.030 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23499372 ● Search Scopus @ Elsevier (PMID): 23499372 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ajpath.2013.01.030 (Tokushima University Institutional Repository: 106071, DOI: 10.1016/j.ajpath.2013.01.030, PubMed: 23499372)
21.	Kato Mika Kaneko, Akiko Kunita, Shinji Abe, Yuta Tsujimoto, Masashi Fukayama, Kaoru Goto, Yoshihiko Sawa, Yasuhiko Nishioka and Yukinari Kato : Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity., Cancer Science, Vol.103, No.11, 1913-1919, 2012. (Summary) Podoplanin is a platelet aggregation-inducing factor associated with tumor metastasis, malignant progression, and cancer stem cells. We produced a rat-human chimeric anti-podoplanin mAb, NZ-8, from rat anti-podoplanin mAb (NZ-1). Although both NZ-1 and NZ-8 possess high binding affinities and high neutralizing activities of platelet aggregation, the antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity of NZ-8 were much higher than NZ-1. Furthermore, both NZ-1 and NZ-8 inhibited the growth of podoplanin-expressing tumors in vivo. Both NZ-1 and NZ-8 also suppressed hematogenous metastasis of podoplanin-expressing tumors. These results suggest that anti-podoplanin mAbs suppressed hematogenous metastasis by both neutralization and antibody-dependent cellular cytotoxicity/complement-dependent cytotoxicity activities. Targeting therapy to podoplanin-expressing tumors should be useful as a novel immunotherapy. (Keyword) Animals / Antibodies, Monoclonal / Antibodies, Neutralizing / Antibody-Dependent Cell Cytotoxicity / Antineoplastic Agents / CHO Cells / Cell Line, Tumor / Complement System Proteins / Cricetinae / Female / Humans / Male / Membrane Glycoproteins / Mice / Mice, Inbred BALB C / Mice, Nude / Neoplasm Metastasis / Neoplasms / Platelet Aggregation / Rats / Rats, Wistar / Recombinant Fusion Proteins (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1349-7006.2012.02385.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22816430 ● Search Scopus @ Elsevier (PMID): 22816430 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1349-7006.2012.02385.x (DOI: 10.1111/j.1349-7006.2012.02385.x, PubMed: 22816430)
22.	Hisao Nemoto, Masaki Kamiya, Aki Nakamoto, Tsuyoshi Matsushita, Kosuke Matsumura, Hatsuhiko Hattori, Tomoyuki Kawamura, Chiaki Taoka, Shinji Abe, Keisuke Ishizawa, Licht Miyamoto and Koichiro Tsuchiya : Synthesis of highly water-soluble fibrate derivatives via BGLation, Bioorganic & Medicinal Chemistry Letters, Vol.22, No.20, 6425-6428, 2012. (Summary) Three water-soluble fibrates (fenofibrate, bezafibrate and chlofibrate) conjugated with a symmetrically branched glyceryl trimer (BGL003) were synthesized, and an evaluation of the fenofibrate-BGL003 conjugate as a candidate for anti-hyperlipemia drug was carried out using rats. The water-solubility of the fenofibrate-BGL003 conjugate was several thousand times greater than that of the original fenofibrate. The lipid-lowering effects of the fenofibrate-BGL003 conjugate were as strong as those of the same grams of fenofibrate. The actual active species of fenofibrate, fenofibric acid, was detected in rats' blood, but neither the fenofibrate-BGL003 conjugate nor fenofibrate was detected, probably due to enzymatic hydrolysis of the ester bond. The plasma concentration of fenofibric acid derived from the fenofibrate-BGL003 conjugate was five times higher than that derived from fenofibrate 4h after administration. (Keyword) Animals / Bezafibrate / Clofibrate / Fenofibrate / Hypolipidemic Agents / Male / Rats / Rats, Sprague-Dawley / Solubility / Triglycerides / Water (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bmcl.2012.08.057 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22975299 ● Search Scopus @ Elsevier (PMID): 22975299 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bmcl.2012.08.057 (DOI: 10.1016/j.bmcl.2012.08.057, PubMed: 22975299)
23.	Hisao Nemoto, Ayato Katagiri, Masaki Kamiya, Tomoyuki Kawamura, Tsuyoshi Matsushita, Kosuke Matsumura, Tomohiro Itou, Hatsuhiko Hattori, Miho Tamaki, Keisuke Ishizawa, Licht Miyamoto, Shinji Abe and Koichiro Tsuchiya : Synthesis of paclitaxel-BGL conjugates, Bioorganic & Medicinal Chemistry, Vol.20, No.18, 5559-5567, 2012. (Summary) Four kinds of symmetrically branched oligoglyceryl trimeric (BGL003)-paclitaxel conjugates and a corresponding heptameric (BGL007) conjugate were synthesized. Molecular weights of all the compounds were less than two times that of paclitaxel. The anti-tumor activity of the most water-soluble BGL003 conjugate was examined and found to be preserved in spite of the chemical modification that is displacement of the N3'-debenzoyl residue with the BGL003 succinyl residue. (Keyword) Animals / Antineoplastic Agents, Phytogenic / Cell Line, Tumor / Dose-Response Relationship, Drug / Glycerol / Humans / Male / Mice / Mice, Inbred BALB C / Mice, Nude / Molecular Conformation / Molecular Weight / Neoplasms, Experimental / Paclitaxel / Solubility / Structure-Activity Relationship / Xenograft Model Antitumor Assays (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bmc.2012.07.031 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22892212 ● Search Scopus @ Elsevier (PMID): 22892212 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bmc.2012.07.031 (DOI: 10.1016/j.bmc.2012.07.031, PubMed: 22892212)
24.	Yuya Horinouchi, Takumi Sakurada, Toshimi Nakamura, Soichiro Tajima, Hirotaka Nishisako, Shinji Abe, Kazuhiko Teraoka, Toshihide Kujime, Kazuyoshi Kawazoe and Kazuo Minakuchi : Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer, Journal of the Pharmaceutical Society of Japan, Vol.131, No.8, 1251-1257, 2011. (Summary) Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) for treatment of metastatic colorectal cancer. Recently, much evidence has suggested that bevacizumab-induced hypertension might be predictive of the effect of bevacizumab. The aim of our study is to retrospectively assess the relationship between the onset of hypertension and the activity of bevacizumab in Japanese metastatic colorectal cancer patients. Between July 2007 and December 2010, 36 patients (median age 66 years; 36-81 years) with metastatic colorectal cancer were assigned to receive bevacizumab in combination with either mFOLFOX6 (5-FU, levofolinate and oxaliplatin) or FOLFIRI (5-FU, levofolinate and irinotecan) at the Tokushima University Hospital. A patient who had increase by >20 mmHg in diastolic blood pressure or had increase to >150/100 mmHg or received antihypertensive treatment was defined as hypertensive. The objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS) were compared between the hypertensive group (n=10) and non-hypertensive group (n=26). ORR and DCR were 60.0% and 100%, respectively, in the hypertensive group and ORR and DCR were 23.1% and 80.8%, respectively, in the non-hypertensive group. These differences were statistically significant (p<0.05). The median PFS tended to be longer in the hypertensive group (65.0 weeks) than in the non-hypertensive group (40.0 weeks). Our data suggested that bevacizumab-induced hypertension may be predictive of the effect of bevacizumab in Japanese metastatic colorectal cancer patients. (Keyword) Adult / Aged / Aged, 80 and over / Angiogenesis Inhibitors / Antibodies, Monoclonal, Humanized / Antineoplastic Combined Chemotherapy Protocols / Asian Continental Ancestry Group / Bevacizumab / blood pressure / Camptothecin / Colorectal Neoplasms / Disease-Free Survival / Female / Fluorouracil / Forecasting / Humans / hypertension / Leucovorin / Male / Middle Aged / Molecular Targeted Therapy / Organoplatinum Compounds / Retrospective Studies / Treatment Outcome / Vascular Endothelial Growth Factor A (Link to Publication Site) ● Publication site (DOI): 10.1248/yakushi.131.1251 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21804330 ● CiNii @ National Institute of Informatics (CRID): 1390001206126575616 ● Summary page in Scopus @ Elsevier: 2-s2.0-79961038711 (DOI: 10.1248/yakushi.131.1251, PubMed: 21804330, CiNii: 1390001206126575616, Elsevier: Scopus)
25.	Youichi Sato, Sakura Kosioka, Yasushi Kirino, Takayuki Kamimoto, Kazuyoshi Kawazoe, Shinji Abe, Kazuo Minakuchi and Yutaka Nakahori : Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway., Life Sciences, Vol.88, No.1-2, 43-49, 2011. (Summary) We previously reported that dipeptidyl peptidase IV (DPP4)-deficient rats were susceptible to dyslipidemia induced by streptozotocin (STZ). Hence, it is suggested that DPP4 is important for lipid metabolism. In this study, to verify the role of DPP4 in the development of dyslipidemia, we carried out a microarray analysis of the livers of STZ-treated wild-type and DPP4-deficient rats and showed that the expression levels of genes involved in metabolic processes (steroid metabolic processes and cellular lipid metabolic processes) were significantly altered by STZ treatment. In the wild-type rats, the expression of hydroxysteroid (17-beta) dehydrogenase 2 (Hsd7b2), which catalyzes sex steroid synthesis from cholesterol, was significantly increased by about 15-fold after STZ treatment; however, it did not change in the DPP4-deficient rats. In the STZ untreated group of DPP4-deficient rats, the expression levels of cytochrome P450, subfamily 51 (Cyp51) and sterol-C4-methyl oxidase-like (Sc4mol), which catalyze intermediate steps in cholesterol synthesis, were significantly elevated compared to those of other groups. Similar results were demonstrated in HuH7-cells after DPP4 overexpression or the addition of human sera containing DPP4. DPP4 is crucial for regulating the expression of factors related to steroid metabolism such as Cyp51, Sc4mol, and Hsd17b2, and DPP4 deficiency or inhibition may cause dyslipidemia. (Keyword) Animals / Cell Line / Cholesterol / Dipeptidyl Peptidase 4 / Dyslipidemias / Estradiol Dehydrogenases / Humans / Lipid Metabolism / Liver / Male / Oligonucleotide Array Sequence Analysis / Rats / Rats, Inbred F344 / Reverse Transcriptase Polymerase Chain Reaction / Sterol 14-Demethylase / Streptozocin (Link to Publication Site) ● Publication site (DOI): 10.1016/j.lfs.2010.10.019 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21047519 ● Search Scopus @ Elsevier (PMID): 21047519 ● Search Scopus @ Elsevier (DOI): 10.1016/j.lfs.2010.10.019 (DOI: 10.1016/j.lfs.2010.10.019, PubMed: 21047519)
26.	Koichiro Tsuchiya, Shuhei Tomita, Keisuke Ishizawa, Shinji Abe, Yasumasa Ikeda, Yoshitaka Kihira and Toshiaki Tamaki : Dietary nitrite ameliorates renal injury in l-NAME-induced hypertensive rats, Nitric Oxide: Biology and Chemistry, Vol.22, No.2, 98-103, 2010. (Summary) Nitric oxide (NO) has numerous important functions in the kidney, and long-term blockage of nitric oxide synthases in rats by L-NAME results in severe hypertension and progressive kidney damage. On the other hand, NO production seems to be low in patients with chronic kidney disease (CKD), and NO deficiency may play a role in CKD progression. In this review, we summarized the mechanisms of amelioration of renal injury induced by L-NAME treated rats by treatment of nitrite. First, we demonstrate whether orally-administrated nitrite-derived NO can shift to the circulation. When 3mg/kg body weight Na(15)NO(2) was orally administered to rats, an apparent EPR signal derived from Hb(15)NO (A(z)=23.4 gauss) appeared in the blood, indicating that orally ingested nitrite can be a source of NO in vivo. Next, in order to clarify the capacity of nitrite to prevent renal disease, we administered low-dose nitrite (LDN: 0.1mg of sodium nitrite in 1L of drinking water), medium-dose nitrite (MDN: 1mg sodium nitrite/L, which corresponds to the amount of nitrite ingested by vegetarians), or high-dose nitrite (HDN: 10mg sodium nitrite/L) to rats simultaneously with L-NAME (1 g l-NAME/L) for 8 weeks, then examined the blood NO level as a hemoglobin-NO adduct (iron-nitrosyl-hemoglobin) using electron paramagnetic resonance spectroscopy, urinary protein excretion, and renal histological changes at the end of the experiment. It was found that oral administration of MDN and HDN but not LDN increased the blood iron-nitrosyl-hemoglobin concentration to the normal level, ameliorated the L-NAME-induced proteinuria, and reduced renal histological damage. The findings demonstrate that chronic administration of a mid-level dietary dose of nitrite restores the circulating iron-nitrosyl-hemoglobin levels reduced by L-NAME and that maintenance of the circulating iron-nitrosyl-hemoglobin level in a controlled range protects against L-NAME-induced renal injury. Taking these findings together, we propose that dietary supplementation of nitrite is a potentially useful nonpharmacological strategy for maintaining circulating NO level in order to prevent or slow the progression of renal disease. It had been believed that nitrite could result in intragastric formation of nitrosamines, which had been linked to esophageal and other gastrointestinal cancers. However, there is no positive association between the intake of nitrate or nitrite and gastric and pancreatic cancer by recent researches. Furthermore, nitrate-derived NO formation pathway is a possible mechanism for the hypotensive effect of vegetable- and fruit-rich diets, which may explain, at least in part, the mechanism of the Dietary Approach to Stop Hypertension (DASH) diet-induced hypotensive and organ-protective effects. Further research is needed to investigate the interaction between nitrite-nitrate intakes and human health. (Keyword) Animals / Diet / Hypertension / Kidney Diseases / NG-Nitroarginine Methyl Ester / Rats / Sodium Nitrite (Link to Publication Site) ● Publication site (DOI): 10.1016/j.niox.2009.12.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20005970 ● Search Scopus @ Elsevier (PMID): 20005970 ● Search Scopus @ Elsevier (DOI): 10.1016/j.niox.2009.12.002 (DOI: 10.1016/j.niox.2009.12.002, PubMed: 20005970)
27.	下岡幸恵, 鳥井真由美, 伊勢夏子, Shinji Abe, 島原由美子, Kazuyoshi Kawazoe, Yasuhiro Kuroda, Hitoshi Houchi and Kazuo Minakuchi : Assessment of Pharmacokinetics of Midazolam for Dose Adjustment in Patients Undergoing Brain Hypothemia Therapy, TDM研究, Vol.27, No.1, 33-38, 2010.
28.	Kazuyoshi Kawazoe, 坂本久美子, 伏谷秀治, Shinji Abe, 久次米敏秀, Kazuhiko Teraoka and Kazuo Minakuchi : 現役薬剤師を対象とした漢方薬意識調査, Japanese Journal of Pharmaceutical Health Care and Sciences, Vol.35, No.5, 351-359, 2009. (Keyword) questionnaire survey / cluster analysis / Kampo / lifetime education / pharmacist / Tokushima (Link to Publication Site) ● Publication site (DOI): 10.5649/jjphcs.35.351 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282679754118272 ● Search Scopus @ Elsevier (DOI): 10.5649/jjphcs.35.351 (DOI: 10.5649/jjphcs.35.351, CiNii: 1390282679754118272)
29.	Shinji Abe, Hideki Ohnishi, Koichiro Tsuchiya, Keisuke Ishizawa, Mayumi Torii, Yasuhisa Kanematsu, Kazuyoshi Kawazoe, Kazuo Minakuchi, Masanori Yoshizumi and Toshiaki Tamaki : Calcium and reactive oxygen species mediated Zn²⁺-induced apoptosis in PC12 cells, Journal of Pharmacological Sciences, Vol.102, No.1, 103-111, 2006. (Summary) The release of excessive Zn(2+) from presynaptic boutons into extracellular regions contributes to neuronal apoptotic events, which result in neuronal cell death. However, the mechanisms of Zn(2+)-induced neuronal cell death are still unclear. Therefore, we investigated the dynamics of intracellular Zn(2+), calcium, and reactive oxygen species in PC12 cells. The addition of Zn(2+) produced cell death in a concentration- and time-dependent manner. (45)Ca(2+) influx occurred just after the treatment with Zn(2+), although subsequent hydroxyl radical (()OH) production did not begin until 3 h after Zn(2+) exposure. ()OH production was significantly attenuated in Ca(2+)-free medium or by L-type Ca(2+) channel antagonist treatment, but it was independent of the intracellular Zn(2+) content. Dantrolene treatment had no protective effects against Zn(2+)-induced cell death. Treatment with N-acetyl-L-cysteine blocked ()OH generation and subsequent cell death. These data indicate that Ca(2+) influx and subsequent ()OH production are critical events in Zn(2+)-induced toxicity in PC12 cells. (Keyword) Acetylcysteine / Animals / Apoptosis / Bisbenzimidazole / Calcium / Calcium Channel Blockers / Calcium Channels, L-Type / Calcium Radioisotopes / Cell Survival / Dantrolene / Fluorescent Dyes / Free Radical Scavengers / Hydroxyl Radical / PC12 Cells / Rats / Reactive Oxygen Species / Spectrophotometry, Atomic / Zinc (Link to Publication Site) ● Publication site (DOI): 10.1254/jphs.FP0060342 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16990703 ● Search Scopus @ Elsevier (PMID): 16990703 ● Search Scopus @ Elsevier (DOI): 10.1254/jphs.FP0060342 (DOI: 10.1254/jphs.FP0060342, PubMed: 16990703)
30.	Yasuhisa Kanematsu, Koichiro Tsuchiya, Hideki Onishi, Yuki Motobayashi, Yuki Izawa, Manabu Ishihara, Keisuke Ishizawa, Shinji Abe, Kazuyoshi Kawazoe and Toshiaki Tamaki : Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nω-nitro-L-arginine methyl ester-treated rats, Hypertension Research, Vol.29, No.5, 369-374, 2006. (Summary) We previously succeeded in measuring the nitrosylhemoglobin (HbNO) level as an index of blood nitric oxide (NO) by the electron paramagnetic resonance (EPR) HbNO signal subtraction method. In this study, we examined the effects of olmesartan, an angiotensin II type 1 receptor blocker (ARB), on NO dynamics in N(omega)-nitro-L-arginine methyl ester (L-NAME)-treated rats by the EPR-subtraction method. Oral administration of L-NAME for 2 weeks induced serious hypertension, and the HbNO concentration was reduced to 37.6% of the level in controls. Coadministration of olmesartan improved hypertension and increased the blood HbNO concentration of L-NAME-treated rats. In contrast, coadministration of hydralazine improved hypertension but did not affect the blood HbNO concentration. In conclusion, our findings suggested that chronic administration of olmesartan ameliorated the endothelial dysfunction in L-NAME-treated rats. (Keyword) Angiotensin II Type 1 Receptor Blockers / Animals / Antihypertensive Agents / Blood Pressure / Body Weight / Electron Spin Resonance Spectroscopy / Endothelium, Vascular / Heart Rate / Hemodynamics / Hemoglobins / Hydralazine / Hypertension / Imidazoles / Male / NG-Nitroarginine Methyl Ester / Nitric Oxide / Rats / Rats, Sprague-Dawley / Tetrazoles (Link to Publication Site) ● Publication site (DOI): 10.1291/hypres.29.369 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16832158 ● Search Scopus @ Elsevier (PMID): 16832158 ● Search Scopus @ Elsevier (DOI): 10.1291/hypres.29.369 (DOI: 10.1291/hypres.29.369, PubMed: 16832158)
31.	Koichiro Tsuchiya, Kaori Akai, Akira Tokumura, Shinji Abe, Toshiaki Tamaki, Yoshiharu Takiguchi and Kenji Fukuzawa : Oxygen radical photo-induced by ferric nitrilotriacetate complex, Biochimica et Biophysica Acta (BBA) - General Subjects, Vol.1725, No.1, 111-119, 2005. (Summary) This study examined the photo-induced generation of reactive oxygen species (ROS) by the carcinogenic iron(III)-NTA complex. Iron(III)-NTA complex (1:1) has three conformations (type (a) in acidic conditions of pH 1-6, type (n) in neutral conditions of pH 3-9, and type (b) in basic conditions of pH 7-10) with two pK(a) values (pK(a1) approximately 4, pK(a2) approximately 8). The iron(III)-NTA complex was reduced to iron(II) under cool-white fluorescent light without the presence of any reducing agent, and the reduction rates of the three conformations of iron(III)-NTA were in the order type (a)>type (n)>type (b) as reported previously (Akai K. et al., Free Radic. Res. 38, 951-962, 2004). ROS generation was investigated by electron paramagnetic resonance (EPR) spectroscopy with a spin-trapping technique. Apparent EPR signals attributed to PBN/(13)CH(3) and PBN/OCH(3) spin adducts were observed after incubation of the iron(III)-NTA complex was mixed with alpha-phenyl-tert-butylnitrone (PBN) and (13)C-DMSO in an aerobic condition. The addition of catalase effectively attenuated the PBN adducts, but superoxide dismutase enhanced them. Taken together, these results indicate that the iron(III)-NTA complex is spontaneously reduced to the iron(II)-NTA complex by light under acidic to neutral pH, and in turn transfers an electron to molecular oxygen to form ROS. (Keyword) Catalase / Cyclic N-Oxides / Electron Spin Resonance Spectroscopy / Ferric Compounds / Free Radicals / Light / Nitrilotriacetic Acid / Nitrogen Oxides / Oxygen / Photochemistry / Superoxide Dismutase / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbagen.2005.05.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15950386 ● Search Scopus @ Elsevier (PMID): 15950386 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbagen.2005.05.001 (DOI: 10.1016/j.bbagen.2005.05.001, PubMed: 15950386)
32.	Yoshihiko Fujita, Koichiro Tsuchiya, Shinji Abe, Yohiharu Takiguchi, Shin-ichi Kubo and Hiromu Sakurai : Estimation of the age of human bloodstains by electron paramagnetic resonance spectroscopy: Long-term controlled experiment on the effects of environmental factors, Forensic Science International, Vol.152, No.1, 39-43, 2005. (Summary) In this study, we examined the efficacy and limitations of electron paramagnetic resonance (EPR) for estimating the age of human bloodstains. At 77K, human bloodstains give four striking EPR signals in the g=6.2 (g6), 4.3 (g4), 2.27 (H) and 2.005 (R) regions due to ferric high-spin, ferric non-heme, ferric low-spin and free radical species, respectively. We found that plotting double logarithms of the EPR intensity ratio of H/g4 versus days past bleeding gave a linear correlation up to 432 days with an error range within 25% of the actual number of days under controlled conditions. However, environmental factors such as differences of absorbent, light exposure and fluctuations of storage temperature affected the changes of these EPR-active compounds, which result in misestimation of the time since bleeding occurred. Therefore, one should take such factors into account in estimating the period since bleeding by this method. (Keyword) Absorption / Aging / Blood Stains / Electron Spin Resonance Spectroscopy / Ferric Compounds / Forensic Medicine / Humans / Light / Nonheme Iron Proteins / Temperature (Link to Publication Site) ● Publication site (DOI): 10.1016/j.forsciint.2005.02.029 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15939175 ● Search Scopus @ Elsevier (PMID): 15939175 ● Search Scopus @ Elsevier (DOI): 10.1016/j.forsciint.2005.02.029 (DOI: 10.1016/j.forsciint.2005.02.029, PubMed: 15939175)
33.	Nermin Ali, Masanori Yoshizumi, Koichiro Tsuchiya, Moe Kyaw, Yoshiko Fujita, Yuki Izawa, Shinji Abe, Yasuhisa Kanematsu, Shoji Kagami and Toshiaki Tamaki : Ebsalen inhibits p38MAP kinase-mediated endothelial cell death by hydrogen peroxide., European Journal of Pharmacology, Vol.485, No.1-3, 127-135, 2004. (Summary) Ebselen (2-phenyl-1, 2-benzisoselenazol-3[2H]-one) is a seleno-organic compound exhibiting both glutathione peroxidase and antioxidant activity. Although it has been reported that ebselen is effective against hydrogen peroxide (H(2)O(2))-induced cell death in several cell types, its effect on endothelial cell damage has not yet been elucidated. In the present study, we examined the effect of ebselen on H(2)O(2)-induced human umbilical vein endothelial cells (HUVECs) death, and its intracellular mechanism. Our findings showed that pretreatment of HUVECs with ebselen resulted in a significant recovery from H(2)O(2)-induced cell death in a concentration-dependent manner. In addition to the inhibition of lactate dehydrogenase (LDH) leakage, ebselen inhibited H(2)O(2)-induced cytochrome c release and caspase-3 activation and the resultant apoptosis in HUVECs. Moreover, it was observed that H(2)O(2) significantly stimulated activation of mitogen-activated protein (MAP) kinases, i.e., p38 MAP kinase, c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK1/2). Ebselen inhibited H(2)O(2)-induced p38 MAP kinase, but not JNK or ERK1/2 activation. Furthermore, SB203580 (4-[4-fluorophenyl]-2-[4-methylsulfinylphenyl]-5-[4-pyridyl]-1H-imidazole), a specific p38 MAP kinase inhibitor, inhibited H(2)O(2)-induced p38 MAP kinase phosphorylation, cytochrome c release, caspase-3 activation, as well as cell death in HUVECs. These findings suggest that ebselen attenuates H(2)O(2)-induced endothelial cell death through the inhibition of signaling pathways mediated by p38 MAP kinase, caspase-3, and cytochrome c release. Thus, inhibition of p38 MAP kinase by ebselen may imply its usefulness for prevention and/or treatment of endothelial cell dysfunction, which was suggested to be the first step in the development of atherosclerosis. (Keyword) Azoles / cell death / Cell Survival / Dose-Response Relationship, Drug / Endothelial Cells / Enzyme Inhibitors / Humans / hydrogen peroxide / Mitogen-Activated Protein Kinases / Organoselenium Compounds / p38 Mitogen-Activated Protein Kinases (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejphar.2003.11.079 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14757132 ● Search Scopus @ Elsevier (PMID): 14757132 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejphar.2003.11.079 (DOI: 10.1016/j.ejphar.2003.11.079, PubMed: 14757132)
34.	Shinji Abe, Kazuyoshi Kirima, Koichiro Tsuchiya, Masumi Okamoto, Toyoshi Hasegawa, Hitoshi Houchi, Masanori Yoshizumi and Toshiaki Tamaki : The reaction rate of edaravone ( 3-methyl-1-phenyl-2-pyrazolin-5-one(MCI-186) with hydroxyl radical., Chemical & Pharmaceutical Bulletin, Vol.52, No.2, 186-191, 2004. (Summary) The pyrazoline derivative edaravone is a potent hydroxyl radical scavenger that has been approved for attenuation of brain damage caused by ischemia-reperfusion. In the present work, we first determined the rate constant, k(r), at which edaravone scavenges radicals generated by a Fenton reaction in aqueous solution in the presence of the spin trap agent, 5,5-dimethyl-1-pyrroline-N-oxide (DMPO), which competed with edaravone. We detected the edaravone radicals in the process of hydroxyl radical scavenging and found that edaravone reacts with hydroxyl radical around the diffusion limit (k(r)=3.0 x 10(10) M(-1) s(-1)). The EPR (electron paramagnetic resonance) spectrum of the edaravone radical was observed by oxidation with a horseradish peroxidase-hydrogen peroxide system using the fast-flow method. This radical species is unstable and changed to another radical species with time. In addition, it was found that edaravone consumed molecular oxygen when it was oxidized by horseradish peroxidase (HRP)-H(2)O(2) system, and that edaravone was capable of providing two electrons to the electrophiles. The possible mechanisms for oxidation of edaravone were investigated from these findings. (Keyword) Antipyrine / Cyclic N-Oxides / Electron Spin Resonance Spectroscopy / Free Radical Scavengers / Hydroxyl Radical / Oxidation-Reduction / Spin Trapping (Link to Publication Site) ● Publication site (DOI): 10.1248/cpb.52.186 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14758002 ● CiNii @ National Institute of Informatics (CRID): 1390001204168756992 ● Search Scopus @ Elsevier (PMID): 14758002 ● Search Scopus @ Elsevier (DOI): 10.1248/cpb.52.186 (DOI: 10.1248/cpb.52.186, PubMed: 14758002, CiNii: 1390001204168756992)
35.	Toyoshi Hasegawa, Atsushi Bando, Koichiro Tsuchiya, Shinji Abe, Masumi Okamoto, Kazuyoshi Kirima, Satoru Ueno, Masanori Yoshizumi, Hitoshi Houchi and Toshiaki Tamaki : Enzymatic and non-enzymatic formation of reactive oxygen species from 6-anilino-5,8-quinolineequinone, Biochimica et Biophysica Acta (BBA) - General Subjects, Vol.1670, No.1, 19-27, 2004. (Summary) The nonenzymatic and enzymatic formation of reactive oxygen species (ROS) from LY83583 (6-anilino-5,8-quinolinequinone) was investigated by electron paramagnetic resonance (EPR) spectroscopy. In the presence of thiol compounds such as glutathione and L-cysteine, LY83583 underwent a one-electron reduction due to low redox potential (-0.3+/-0.01 V vs. SCE), followed by formation of LY83583 semiquinone anion radical. This species was characterized by EPR spectroscopy under an argon atmosphere at neutral pH. Under an aerobic condition, this species interacts with molecular oxygen to form a superoxide anion radical. GSH-conjugated LY83583 was also identified by NMR and FAB-MS. When LY83583 was applied to PC12 cells, ROS formation was completely inhibited by both the flavoenzyme inhibitor DPI and the DT-diaphorase inhibitor dicumarol. On the other hand, ROS generation occurred independent of intracellular GSH level. These results indicate that LY83583 can generate ROS both enzymatically and nonenzymatically, although the enzymatic formation is dominant over the nonenzymatic system in PC12 cells. (Keyword) Aminoquinolines / Animals / Chromatography, High Pressure Liquid / Cyclic N-Oxides / Electrochemistry / Electron Spin Resonance Spectroscopy / Enzyme Inhibitors / Glutathione / Glutathione Disulfide / Magnetic Resonance Spectroscopy / Mass Spectrometry / Molecular Structure / Oxygen Consumption / PC12 Cells / Rats / Reactive Oxygen Species / Spin Trapping (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbagen.2003.10.008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14729138 ● Search Scopus @ Elsevier (PMID): 14729138 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbagen.2003.10.008 (DOI: 10.1016/j.bbagen.2003.10.008, PubMed: 14729138)
36.	Yuki Suzaki, Masanori Yoshizumi, Yukio Yamashita, Shinji Abe, Koichiro Tsuchiya, Yumiko Satoh, Yasuhiro Kuroda, Kazuya Horike, Masashi Kano, Yoshio Fukuta, Takashi Kitaichi, Takaki Hori, Yutaka Masuda, Tetsuya Kitagawa, Kazuo Minakuchi and Toshiaki Tamaki : Determination of plasma concentrations of endothelin-1(1-31) and endothelin-1 in healthy subjects and patients with atherosclerosis., Journal of Cardiovascular Pharmacology, Vol.41, No.suppl.1, S83-S87, 2003. (Summary) We previously found that human chymase cleaves big endothelins at the Tyr31-Gly32 bond and produces 31-amino-acid endothelins, endothelins(1-31). Endothelin-1(1-31) has been isolated from a number of human organs, including the heart and lungs. As endothelin-1 has been shown to play a significant role in the paracrine regulation of cardiovascular functions in humans, it is possible that endothelin-1(1-31) may also exhibit biological activity on human tissues. We previously reported that synthetic endothelin-1(1-31) exhibits a number of physiological actions on cultured cells in vitro. In the present study, we investigated the plasma concentrations of endothelin-1(1-31) and endothelin-1 in healthy subjects and compared them with those in patients with cardiovascular diseases. Endothelin-1(1-31) and endothelin-1 in human plasma was measured using a sandwich-enzyme-immunoassay system, which was recently described for measurement of endothelin-1(1-31). The plasma concentrations of endothelin-1(1-31) and endothelin-1 in healthy volunteers were 19.24 +/- 5.70 and 15.54 +/- 4.45 pg/ml (n = 5), respectively. We also measured plasma concentrations of endothelin-1(1-31) and endothelin-1 before and after surgery in patients with abdominal aortic aneurysms. Before surgery, plasma concentrations of endothelin-1(1-31) and endothelin-1 in these patients were higher than those in healthy individuals. After surgery, both endothelin-1(1-31) and endothelin-1 in plasma decreased to levels similar to those of healthy subjects. This suggests that endothelin-1(1-31) may have similar physiological significance to endothelin-1 in patients with atherosclerosis. (Keyword) Adult / Aged / Aortic Aneurysm, Abdominal / Arteriosclerosis / Endothelin-1 / Humans / Male / Middle Aged / Peptide Fragments (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12688403 ● Search Scopus @ Elsevier (PMID): 12688403 (PubMed: 12688403)
37.	Moe Kyaw, Masanori Yoshizumi, Koichiro Tsuchiya, Kasuyoshi Kirima, Yuki Suzaki, Shinji Abe, Toyoshi Hasegawa and Toshiaki Tamaki : Antioxidants inhibit endothelin-1(1-31)-induced proliferation of vascular smooth muscle cells via the inhibition of mitogen-activated protein (MAP) kinase and activator protein-1 (AP-1)., Biochemical Pharmacology, Vol.64, No.10, 1521-1531, 2002. (Link to Publication Site) ● Publication site (DOI): 10.1016/S0006-2952(02)01349-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12417265 ● Search Scopus @ Elsevier (PMID): 12417265 ● Search Scopus @ Elsevier (DOI): 10.1016/S0006-2952(02)01349-7 (DOI: 10.1016/S0006-2952(02)01349-7, PubMed: 12417265)

Review, Commentary:

1.	Yasuhiko Nishioka and Shinji Abe : Development of novel anti-podoplanin antibodies against malignant pleural mesothelioma, Seikagaku, Vol.89, No.4, 564-567, Aug. 2017. (Link to Publication Site) ● Publication site (DOI): 10.14952/SEIKAGAKU.2017.890564 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390283684847016832 ● Summary page in Scopus @ Elsevier: 2-s2.0-85042868606 (DOI: 10.14952/SEIKAGAKU.2017.890564, CiNii: 1390283684847016832, Elsevier: Scopus)
2.	Yasuhiko Nishioka, Shinji Abe, Hiroaki Yanagawa, Minoru Irahara and Saburo Sone : 樹状細胞による肺癌の免疫療法, コンセンサス癌治療, Vol.4, No.4, 218-219, 2005.
3.	Yasuhiko Nishioka, Shinji Abe, Hiroaki Yanagawa, Minoru Irahara and Saburo Sone : 特集:コンセンサス肺癌の治療，トピックス:樹状細胞による肺癌の免疫療法, コンセンサス癌治療, Vol.4, No.4, 218-219, 2005.

Proceeding of International Conference:

1.	Kei Kawada, Ishida Tomoaki, Morisawa Shumpei, Jobu Kohei, Higasi Youichirou, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : Atractylodes lancea Rhizome-derived Exosome-like Nanoparticles Suppress Lipopolysaccharide-induced Inflammation in Murine Microglial Cells, 81st FIP World Congress of Pharmacy and Pharmaceutical Sciences., Brisbane, Sep. 2023.
2.	S Morizumi, S Sato, Shinji Abe, H Okazaki, C Yanjuan, Hisatsugu Goto, Masaki Hanibuchi, Yoshinori Aono, Hirohisa Ogawa, Masaki Hanibuchi, Hisanori Uehara and Yasuhiko Nishioka : Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity., ERS2016 International Conference, Sep. 2016.
3.	Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Shinji Abe, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G Ledford, Saburo Sone and Yasuhiko Nishioka : Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response, Joint Meeting to Seoul National University, Seoul, Dec. 2012.
4.	Yasuhiko Nishioka, Shinji Abe, Yuki Morita, Mika K Kaneko, Masaki Hanibuchi, Hisatsugu Goto, Souji Kakiuchi, Yoshinori Aono, Jun Huang, Atsushi Mitsuhashi, Seidai Sato, Kazuo Minakuchi and Yukinari Kato : Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma, 14th International Biennial Congress of the Metastasis Research Society, Brisbane, Sep. 2012.
5.	Yasuhiko Nishioka, Shinji Abe, Mika K Kaneko, Yoshinori Aono, Jun Huang, Hisatsugu Goto, Masatoshi Kishuku, Masaki Hanibuchi, Saburo Sone, Kazuo Minakuchi and Yukinari Kato : Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma via ADCC, ATS 2012 International Conference, San Francisco, May 2012.
6.	Ikuta Kenji, Ise Natsuko, Shimooka Yukie, Katagiri Yuki, Shinji Abe, Kazuhiko Teraoka, Kujime Toshihide, Kazuyoshi Kawazoe and Kazuo Minakuchi : Pharmaceutical and economical role of clinical phamacist in emergency and critical care medicine, 46th ASHP Midyear Clinical Meeting and Exhibition, New Orleans, Dec. 2011.
7.	Masaki Hanibuchi, Shinji Abe, Masatoshi Kishuku, Souji Kakiuchi, Kazuyoshi Kawazoe, Kazuo Minakuchi, Mika K. Kaneko, Yukinari Kato and Yasuhiko Nishioka : Targeted therapy for mesothelioma using anti-podoplanin antibody NZ-1 via ADCC, 5th EORTC-NCI-ASCO Annual Meeting on 'Molecular Markers in Cancer', Brussels, Belgium, Oct. 2011.
8.	Yuya Horinouchi, Takumi Sakurada, Toshimi Nakmura, Tsuyoshi Mori, Ken Konaka, Soichiro Tajima, Shinji Abe, Kazuhiko Teraoka, Toshihide Kujime, Kazuyoshi Kawazoe, Hitoshi Houchi and Kazuo Minakuchi : Correlation between development of hypertension and efficay in metastatic colorectal cancer patients treated with bevacizumab, Abstracts of 10th Congress of the Europian Association for Clinical Pharmacology and Therapeutics, Vol.109, No.S1, 57, Budapest, Jun. 2011.
9.	Huang Jun, Yasuhiko Nishioka, Shinji Abe, Morita Yuki, Ozaki Shuji, Verma Kumar Vinod, Kishuku Masatoshi, Minakuchi Kazuo, Sekido Yoshitaka, Matsumoto Toshio and Saburo Sone : Anti-HM1.24 antibodies induce antibody-dependent cellular cytitixicity against mesothelioma cells., IMIG2010 (The 10th International Conference of the International Mesothelioma Interest Group), Kyoto, Sep. 2010.
10.	Takeshi Mori, Nishisako Hirotaka, Nakamura Toshimi, Yuya Horinouchi, Sakurada Takumi, Shinji Abe, Kazuhiko Teraoka, Kujime Toshihide, Kazuyoshi Kawazoe and Kazuo Minakuchi : Prediction of adverse effects based on cluster analysis by demography and clinical factor in the outpatients treated with cancer chemotherapy, 15th Anniversary Congress of EAHP, Niece, Mar. 2010.
11.	Shinji Abe, Shimooka Yukie, Kujime Toshihide, Kazuhiko Teraoka, Kazuyoshi Kawazoe and Kazuo Minakuchi : A sinple method for prevention of adverse effects in double filtration plasmapheresis (DFPP), Pharmaceutical Sciences World Congress 2007, Amsterdam, Apr. 2007.
12.	Koichiro Tsuchiya, Yuya Horinouchi, Yasuhisa Kanematsu, Shinji Abe, Hideki Ohnishi, Soichiro Tajima, Keisuke Ishizawa, Toshiaki Tamaki and Yoshiharu Takiguchi : Production of nitrosonifedipine radical from nifedipine and its antioxidative activity in cultured cells, 13th annual meeting of society of free radical and biology of medicine, Denver, Nov. 2006.
13.	Hideki Ohnishi, Koichiro Tsuchiya, Yasuhisa Kanematsu, Shinji Abe, Soichiro Tajima and Toshiaki Tamaki : Effects of quercetin on NO production from nitrite at physiological conditions, 20th Scientific Meeting of the International Soiciety of Hypertension, Fukuoka, Japan, Oct. 2006.
14.	Koichiro Tsuchiya, Yasuhisa Kanematsu, Keisuke Ishizawa, Shinji Abe, Hideki Ohnishi, Soichiro Tajima, Kazuyoshi Kawazoe, Yoshiharu Takiguchi and Toshiaki Tamaki : Dietary nitrite is an alternative source of NO in vivo, International Society for Radical Research 13th Biennial Congress, Davos, Switzerland, Aug. 2006.
15.	Koichiro Tsuchiya, Kaori Akai, Akira Tokumura, Shinji Abe, Toshiaki Tamaki, Yoshiharu Takiguchi and Kenji Fukuzawa : Oxygen Radicals Photo-induced by Ferric Nitrilotriacetate(FE-NTA) Complex, EPR 2005, Columbus, OH, Sep. 2005.

Proceeding of Domestic Conference:

1.	Yui Nagao, Chiemi Sato, YAMAKAWA Ayumi, Takaaki Yamamoto, Kei Kawada and Shinji Abe : ビタミンDサプリメントがアレルギー性鼻炎に与える効果の検討―システマティックレビューとメタ解析―, 日本薬学会第144年会(横浜), Mar. 2024.
2.	Licht Miyamoto, Yuki Tsuchihashi, Shinji Abe, Toshihiro Izumi, Aya Hatano, Masaki Imanishi, Yasumasa Ikeda and Koichiro Tsuchiya : 新規水溶性カンプトテシン誘導体，SN38-BGLによる，ヒト肺がん細胞移植モデルマウスにおける抗腫瘍効果と副作用の解析, 第97回日本薬理学会年会(神戸), Dec. 2023.
3.	Shinya Kobayashi, 米田和夫, 田村克也, 福家麻美, HARA Nobuyuki, TAKANEZAWA Masaki, Chiemi Sato, Shinji Abe, 松浦大輔 and 近藤彰 : COVID-19外来診療における医師・病院薬剤師・薬局薬剤師の連携―PBPMを活用した薬物相互作用マネジメント, 第33回日本医療薬学会年会(仙台), Nov. 2023.
4.	Wakako Minami, Chiemi Sato, Takaaki Yamamoto, Kei Kawada and Shinji Abe : 電子版お薬手帳の利用推進における問題点の検討―徳島県の薬局薬剤師に対するアンケート調査より―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
5.	Chisaki Yamaguchi, Chiemi Sato, Yui Nagao, Takaaki Yamamoto, Kei Kawada and Shinji Abe : ベンゾジアゼピン受容体作動薬の服用と認知機能低下の関連性評価 ―システマティックレビューとメタ解析―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
6.	Takuya Wada, Satoshi Itakura, Aito Yoshida, Takaaki Yamamoto, Kei Kawada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗podoplanin抗体chLpMab-23fのMPM胸腔内移植マウスモデルにおける抗腫瘍効果の検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), Oct. 2023.
7.	Satoshi Itakura, Takuya Wada, Aito Yoshida, Takaaki Yamamoto, Kei Kawada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗podoplanin抗体chLpMab-2及びコアフコース除去抗体chLpMab-2fのin vivoにおける抗腫瘍効果の検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), Oct. 2023.
8.	Aito Yoshida, Satoshi Itakura, Takuya Wada, Takaaki Yamamoto, Kei Kawada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗podoplanin抗体のコアフコース除去に伴うADCC増強とNK細胞活性化に関する検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), Oct. 2023.
9.	Kei Kawada, 石田智滉, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来細胞外膜小胞を用いた抗神経炎症治療薬の開発, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
10.	Hiroto Yoneda, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroshi Nokihara, Shinji Abe, 金子美華, 加藤幸成 and Yasuhiko Nishioka : 悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討, 第32回日本がん転移学会学術集会・総会, Jul. 2023.
11.	Kei Kawada, 石田智滉, 常風興平, 森沢惇平, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来Exosome-like Nanoparticles (ELNs)の医療への応用 -蒼朮由来ELNsによる抗神経炎症作用の検討-, 第143回日本薬理学会近畿部会, Jun. 2023.
12.	吉田碧人, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗 podoplanin 抗体 chLpMab-2 のコアフコース除去に伴う ADCC 増強とNK 細胞活性化に関する検討, 第27回日本がん分子標的治療学会学術集会, Jun. 2023.
13.	Chisaki Yamaguchi, Chiemi Sato, Yui Nagao and Shinji Abe : Association between benzodiazepine receptor agonists use and risk of dementia A Systematic review and meta-analysis, 日本薬学会第143年会(札幌), Mar. 2023.
14.	Shinya Kobayashi, 米田和夫, 田村克也, 福家麻美, Shinji Abe, Chiemi Sato, 松浦大輔 and 近藤彰 : COVID-19 外来診療における病院薬剤師の活躍-パキロビッドの薬物相互作用マネジメントを中心に-, 第266回徳島医学会学術大会(徳島), Feb. 2023.
15.	Keichiroh Yamada, Toshihiro Izumi, Satoshi Itakura, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗ポドプラニン抗体 chLpMab-2f の in vitro 及び in vivo における抗腫瘍効果の検討, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(広島), Nov. 2022.
16.	Kana Shinomiya, Takuya Wada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的ヒト化抗ポドプラニン抗体 humLpMab-23f のADCC 及び CDC に関する検討, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(広島), Nov. 2022.
17.	Hikari Fukuda, Aito Yoshida, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : コアフコース除去による抗ポドプラニン抗体の FcR 及び C1q 結合性の変化と細胞傷害活性への影響の検討, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(広島), Nov. 2022.
18.	Yume Iwasa, Chiemi Sato, Chisaki Yamaguchi and Shinji Abe : 糖尿病治療薬SGLT2阻害薬と骨折リスクの関連性評価∼システマティックレビューとメタ解析∼, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(広島), Nov. 2022.
19.	Hiroto Yoneda, Atsushi Mitsuhashi, Hirokazu Ogino, Ryohiko Ozaki, Yohhei Yabuki, Hiroshi Nokihara, Shinji Abe, 加藤幸成 and Yasuhiko Nishioka : 悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討, 第26回日本がん分子標的治療学会学術集会, Jun. 2022.
20.	Hikari Fukuda, Aito Yoshida, Toshihiro Izumi, Keito Kojya, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : 抗ポドプラニン抗体 NZ-12 のコアフコース除去による FcR 及び C1q 結合性への影響, 日本薬学会第142年会 (名古屋online), Mar. 2022.
21.	KAWAHARA Kazuki, Toshihiro Izumi, Kana Shinomiya, Keichiroh Yamada, Takuya Wada, Satoshi Itakura, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗 podoplanin 抗体 chLpMab-23f による悪性胸膜中皮腫に対する抗体依存性細胞障害の検討, 日本薬学会第142年会 (名古屋online), Mar. 2022.
22.	Yume Iwasa, Chiemi Sato, Chisaki Yamaguchi and Shinji Abe : SGLT2阻害薬と他の糖尿病治療薬における骨折リスクの比較検討∼システマティックレビューとメタ解析∼., 日本薬学会第142年会 (名古屋online), Mar. 2022.
23.	Chiemi Sato, Koichiro Tsuchiya and Shinji Abe : 臨床実習後模擬症例演習科目における遠隔授業導入の影響評価∼学生の臨床検査値理解度の分析より∼, 日本薬学会第142年会(名古屋online), Mar. 2022.
24.	Chiemi Sato, Koichiro Tsuchiya and Shinji Abe : 検査値理解度に対するルーブリックの作成と臨床実習後模擬症例演習の有用性評価, Rubric for lab. data comprehension and evaluation of usefulness of clinical case-study program, Mar. 2021.
25.	Karen Matayoshi, Chiemi Sato, Shinzoh Yamamoto and Shinji Abe : 地域医療に貢献できる薬剤師養成を目的としたがん終末期症例に関する教育プログラムの導入とその評価, 第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会 (島根online), Dec. 2020.
26.	Shinzoh Yamamoto, Chiemi Sato, Karen Matayoshi and Shinji Abe : 徳島県に根ざした認知症の在宅症例検討を用いた薬剤師養成教育プログラムの開発とその評価, 第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会 (島根online), Dec. 2020.
27.	Asuka Okemoto, Chiemi Sato, Yume Iwasa and Shinji Abe : プロトンポンプ阻害剤(PPI)の骨に対する影響と安全な投与基準の検討-システマティックレビューとメタ解析-, 第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会 (島根online), Dec. 2020.
28.	KAWAHARA Kazuki, Shinji Abe, 加藤幸成 and Yasuhiko Nishioka : 悪性胸膜中皮腫に対するがん特異的抗 podoplanin 抗体 chLpMab-23f の in vitro における抗腫瘍効果の検討, 第24回日本がん分子標的治療学会学術集会, Oct. 2020.
29.	Licht Miyamoto, Yuko Yagi, Aya Hatano, Yasumasa Ikeda, Shinji Abe, Toshiaki Tamaki and Koichiro Tsuchiya : Chronic exposure to hypoxia facilitates chemotherapy sensitivity with downregulation of MDR1, 日本薬理学会, Mar. 2020.
30.	Karen Matayoshi, Shinji Abe, Shinzoh Yamamoto, Tomoko Tanaka, Chiemi Sato and Tetsuya Kume : 徳島大学における地域に根差した薬剤師養成教育の確立を目的とした在宅チーム医療の実態調査, 日本薬学会第140年会, Mar. 2020.
31.	Asuka Okemoto, Chiemi Sato, Yuri Matsuo, Tomoko Tanaka and Shinji Abe : The effect of PPI on calcium absorption-A systematic review and meta-analysis, 日本薬学会第140年会, Mar. 2020.
32.	Misa Ushirogohchi, Shinji Abe, Toshihiro Izumi, Tomo Matsui, Hiroaki Agata, Fumi Kuriki, Tomoko Tanaka, Chiemi Sato, Kato Yukinari and Yasuhiko Nishioka : がん治療抗体のコアフコース除去による CDC 活性への影響, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
33.	Tomo Matsui, Shinji Abe, Toshihiro Izumi, Misa Ushirogohchi, Hiroaki Agata, Fumi Kuriki, Mayu Miyagawa, Tomoko Tanaka, Chiemi Sato, Kato Yukinari and Yasuhiko Nishioka : がん特異的抗ポドプラニン抗体chLpMab-2fのADCC活性及びCDC活性に関する検討, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
34.	Hiroaki Agata, Shinji Abe, Toshihiro Izumi, Fumi Kuriki, Mayu Miyagawa, Tomoko Tanaka, Chiemi Sato, Kato Yukinari and Yasuhiko Nishioka : 悪性胸膜中皮腫に対するマウス抗マウスポドプラニン抗体を用いたin vivo実験系の作成, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
35.	Fumi Kuriki, Shinji Abe, Toshihiro Izumi, Hiroaki Agata, Misa Ushirogohchi, Tomo Matsui, Mayu Miyagawa, Tomoko Tanaka, Chiemi Sato, Kato Yukinari and Yasuhiko Nishioka : 悪性胸膜中皮腫に対するポドカリキシンを標的とした新規腫瘍特異的抗体医薬の抗腫瘍効果に関する検討, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
36.	Yuri Matsuo, Chiemi Sato, Asuka Okemoto, Tomoko Tanaka and Shinji Abe : 骨損傷時の疼痛管理におけるNSAIDsの安全な投与基準に関する検討:システマティックレビューとメタ解析, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
37.	Toshihiro Izumi, Shinji Abe, Hisatsugu Goto, Kato Yukinari and Yasuhiko Nishioka : Anti-tumor activity of cancer-specific anti-podoplanin mAb chLpMab-2 against malignant plural mesothelioma in vitro., 第23回日本がん分子標的治療学会学術集会, Jun. 2019.
38.	Hiroaki Agata, Shinji Abe, Toshihiro Izumi, Fumi Kuriki, Tomo Matsui, Chiemi Sato, Tomoko Tanaka, Tetsuya Kume, 加藤幸成 and Yasuhiko Nishioka : マウス抗マウスポドプラニン抗体による悪性胸膜中皮腫に対するADCC 活性およびCDC 活性の検討, 日本薬学会第139年会, Mar. 2019.
39.	Toshihiro Izumi, Shinji Abe, Hiroaki Agata, Misa Ushirogohchi, Chiemi Sato, Tomoko Tanaka, Tetsuya Kume, 加藤幸成 and Yasuhiko Nishioka : 悪性胸膜中皮腫に対する抗ポドカリキシン抗体のADCC 活性の検討, 日本薬学会第139年会, Mar. 2019.
40.	Licht Miyamoto, Shinji Abe, Hisao Nemoto and Koichiro Tsuchiya : 分岐鎖オリゴグリセロールを用いた難水溶性化合物の親水化技術と医薬品への応用, 日本薬学会第139年会シンポジウム「薬学に革新をもたらす最先端技術の世界 ∼基礎研究から臨床まで∼」, Mar. 2019.
41.	Yuri Matsuo, Chiemi Sato, Asuka Okemoto, Tomoko Tanaka, Shinji Abe and Tetsuya Kume : NSAIDs が骨治癒に与える影響システマティックレビューとメタ解析, 日本薬学会第139年会, Mar. 2019.
42.	Yasuhiko Nishioka, Shinji Abe, 金子美華, 三橋惇志, Kenji Ohtsuka, Hisatsugu Goto and 加藤幸成 : 悪性胸膜中皮腫に対する新規治療法開発を目指した前臨床研究, 第56回日本癌治療学会学術集会 (パネルディスカッション), Oct. 2018.
43.	山田慎二, 金子美華, 国田朱子, Shinji Abe, 板井俊介, 深山正久, Yasuhiko Nishioka and 加藤幸成 : がん特異的podoplaninを認識するヒトキメラ改変モノクローナル抗体, 第77回日本癌学会総会, Sep. 2018.
44.	板井俊介, 大石智一, 金子美華, 山田慎二, Shinji Abe, Yasuhiko Nishioka, 川田学, 原田浩之 and 加藤幸成 : 口腔扁平上皮癌における抗ポドカリキシン抗体のADCCによる抗腫瘍効果, 第77回日本癌学会総会, Sep. 2018.
45.	Shinji Abe, Chiemi Sato, Tomoko Tanaka and Tetsuya Kume : 薬局実務実習期間中における情報交換会実施の試み, 第3回日本薬学教育学会, Sep. 2018.
46.	Shinji Abe, 加藤幸成 and Yasuhiko Nishioka : 悪性胸膜中皮腫に対するポドプラニンを標的とした抗体療法の開発, 第24回石綿・中皮腫研究会, Oct. 2017.
47.	Chiemi Sato, Shinji Abe, Koichiro Tsuchiya and Tetsuya Kume : 改訂コアカリキュラムに提示された「代表的な疾患」に関する実習状況と今後の課題, 第56回日本薬学会・日本薬剤師会・日本病院薬剤師会学術大会中国四国支部大会, Oct. 2017.
48.	張耀文, 国田朱子, 金子美華, 板井俊介, 山田慎二, 大石智一, Shinji Abe, Yasuhiko Nishioka, 川田学, 深山正久 and 加藤幸成 : ポドカリキシンを標的としたヒトキメラ型抗体chPcMab-47によるヒト大腸がん移植片モデルでの抗腫瘍効果の検討, 第76回日本癌学会総会, Sep. 2017.
49.	山田慎二, 金子美華, 国田朱子, 大石智一, Shinji Abe, 張耀文, 板井俊介, 川田学, 深山正久, Yasuhiko Nishioka and 加藤幸成 : がん特異的podocalyxinを認識するヒトキメラ改変モノクローナル抗体(chPcMab-6)の抗腫瘍効果および安全性, 第76回日本癌学会総会, Sep. 2017.
50.	宗野真和, 松岡一郎, 牧純, Shinji Abe, Youichi Sato, 飯原なおみ, 宮澤宏, 通元夫 and 桐野豊 : 海外の薬学教育(3)―伝統を携え改革に取り組む，イギリス・フランス・ドイツの薬学教育―, 第2回日本薬学教育学会, Sep. 2017.
51.	飯原なおみ, 松岡一郎, Shinji Abe, 宗野真和, 福山愛保, Hiroshi Kiwada and 桐野豊 : 海外の薬学教育(2)― 臨床現場を重視して改革に取り組む，フィンランド・デンマークの薬学教育―, 第2回日本薬学教育学会, Sep. 2017.
52.	Toshihiro Izumi, Shinji Abe, Hirokazu Ogino, Hisatsugu Goto, Masaki Hanibuchi, 加藤幸成 and Yasuhiko Nishioka : 悪性胸膜中皮腫同所移植マウスモデルに対する新規マウス抗ポドプラニン抗体LpMab-21による抗腫瘍効果の検討, 第21回日本がん分子標的学会学術集会, Jun. 2017.
53.	Chiemi Sato, Shinji Abe, Naoto Okada, Koichiro Tsuchiya and Kazuyoshi Kawazoe : 薬物療法における実践的能力育成に向けたルーブリック評価の活用, 日本薬学会第137年会(仙台), Mar. 2017.
54.	御牧夕紀子, Naoto Okada, Shinji Abe, Chiemi Sato, Noriaki Minakawa and Kazuyoshi Kawazoe : 悪性黒色腫患者における抗PD-1抗体療法の治療効果および免疫関連副作用の発現と血中リンパ球数推移との関連性の検討, 第55回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2016.
55.	恒益知宏, Shinji Abe, 和泉俊尋, Chiemi Sato, Naoto Okada, 加藤幸成, Yasuhiko Nishioka and Kazuyoshi Kawazoe : 新規マウス抗PDPN抗体のin vitroにおけるADCC活性の検討, 第55回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2016.
56.	Naoto Okada, 中本亜紀, 田中里奈, 泉侑希, Shinji Abe, Chiemi Sato, Keisuke Ishizawa and Kazuyoshi Kawazoe : qSOFAスコアを用いたカンジダ血漿の重症度分類の有用性, 第55回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2016.
57.	Chiemi Sato, Shinji Abe, Naoto Okada, Tatsuhiro Ishida, Koichiro Tsuchiya, Akira Otaka and Kazuyoshi Kawazoe : 地域薬局における災害対策の現状と課題, 第55回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2016.
58.	Naoto Okada, 御牧夕紀子, 桑原絵美, Yoshihiro Matsudate, Shinji Abe, Chiemi Sato, Yoshiaki Kubo, Keisuke Ishizawa and Kazuyoshi Kawazoe : ニボルマブ投与による末梢血リンパ球比率の変化が副作用発現及び治療効果に与える影響, 第26回日本医療薬学会年会, Sep. 2016.
59.	Shinji Abe, デニスウィリアムズ, Chiemi Sato, Naoto Okada, Koichiro Tsuchiya and Kazuyoshi Kawazoe : ビデオ会議システムを用いた米国薬学部学生との症例検討会実施の試み, 第1回日本薬学教育学会, Aug. 2016.
60.	Kazuyoshi Kawazoe, Shinji Abe, Taro Shimizu, Tatsuhiro Ishida and Akira Otaka : 徳島大学発「インタラクティブYAKUGAKUJIN」の育成―新しい視点に立脚した教育の開発と実践―, 第1回日本薬学教育学大会, Aug. 2016.
61.	Shinji Abe, 加藤幸成, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : ポドプラニンを標的とした抗体療法とペメトレキセドの併用による悪性胸膜中皮腫に対する抗腫瘍効果の検討, 第20回日本がん分子標的治療学会学術集会, May 2016.
62.	Shinji Abe, 加藤幸成, 金子美華, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 悪性胸膜中皮腫に対する新規抗ポドプラニン抗体NZ-12の効果, 第56回日本呼吸器学会学術講演会, Apr. 2016.
63.	和泉俊尋, Shinji Abe, Chiemi Sato, Naoto Okada, 加藤幸成, Yasuhiko Nishioka and Kazuyoshi Kawazoe : 悪性胸膜中皮腫同所移植マウスに対する抗ポドプラニン抗体NZ-12とペメトレキセドの併用効果の検討, 日本薬学会第136年会, Mar. 2016.
64.	Naoto Okada, 花房剛志, Shinji Abe, Chiemi Sato, 中村敏己, Kazuhiko Teraoka, Keisuke Ishizawa and Kazuyoshi Kawazoe : 自家造血幹細胞移植併用大量化学療法における味覚障害の発現に関与する危険因子の探索, 日本薬学会第136年会, Mar. 2016.
65.	Chiemi Sato, Shinji Abe, Naoto Okada, Kaori Yamamoto, Mami Azuma, Koichiro Tsuchiya and Kazuyoshi Kawazoe : 薬局実務実習における能動的な学びの促進と課題解決能力の醸成に向けた連携指導の検討, 日本薬学会第136年会(横浜), Mar. 2016.
66.	Shinji Abe, Chiemi Sato, Kaori Yamamoto, Mami Azuma and Akira Otaka : 薬学体験実習における屋根瓦方式導入の有用性, 第54回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会 (高知), Nov. 2015.
67.	Naoto Okada, Shinji Abe, Chiemi Sato, Mami Azuma, Kazuyoshi Kawazoe, Akira Otaka and Keisuke Ishizawa : 徳島大学病院における模擬体験型学習を用いた実務実習の評価, 第54回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2015.
68.	Chiemi Sato, Kaori Yamamoto, Shinji Abe, Naoto Okada, Koichiro Tsuchiya, Mami Azuma and Akira Otaka : 病院・薬局実務実習における実習生の主体性育成に向けての取組み:課題発見型レポートの効果の検証, 第54回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2015.
69.	土橋有希, Shinji Abe, Licht Miyamoto, 松下剛史, 片桐彩人, Hisao Nemoto and Koichiro Tsuchiya : 分岐鎖オリゴグリセロールを用いたPaclitaxelの物性及び薬効の改善, 第54回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会 (高知), Oct. 2015.
70.	Shinji Abe, 加藤幸成, 金子美華, 大塚憲司, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 新規ヒトキメラ型抗ポドプラニン抗体NZ-12の悪性胸膜中皮腫に対する抗腫瘍効果, 第74回日本癌学会学術総会, Oct. 2015.
71.	Shinji Abe, 土橋有希, Chiemi Sato, Kaori Yamamoto, Licht Miyamoto, Koichiro Tsuchiya, Mami Azuma and Yasuhiko Nishioka : 悪性胸膜中皮腫胸腔内移植マウスに対するヒト・キメラ型抗ポドプラニン抗体NZ-8の効果, 日本薬学会第135年会, Mar. 2015.
72.	Chiemi Sato, Shinji Abe, Kaori Yamamoto and Mami Azuma : 自発的な学びと解決する力を育む探究姿勢型レポートの導入 ∼病院・薬局実務実習における検討∼, 日本薬学会第135年会, Mar. 2015.
73.	Kaori Yamamoto, Shinji Abe, Chiemi Sato and Mami Azuma : 社会薬学教育における薬学生の情報活用に向けた取組, 日本薬学会第135年会(神戸), Mar. 2015.
74.	Shinji Abe, デニスウィリアムズ, Chiemi Sato, Kaori Yamamoto, Mami Azuma and Koichiro Tsuchiya : 屋根瓦方式を用いた症例検討ビデオカンファレンスの有用性, 第53回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2014.
75.	Chiemi Sato, Shinji Abe, Kaori Yamamoto and Mami Azuma : 問題発見解決能力の醸成を目指した徳島大学薬学部での取り組みと分析∼病院・薬局実務実習における有用性∼, 第53回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2014.
76.	Kaori Yamamoto, Shinji Abe, Chiemi Sato and Mami Azuma : 薬学生の情報接触行動についての検討, 第53回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2014.
77.	Mami Azuma, 佐藤友香, Shinji Abe and Chiemi Sato : 薬学生の安全性意識向上に向けての取組∼実務実習におけるインシデントとその報告∼, 第47回日本薬剤師会学術大会, Oct. 2014.
78.	Licht Miyamoto, 渡辺勝志, 土橋有希, 山根萌, 田岡千明, 松下剛史, 笠原真一郎, 神谷昌樹, Keisuke Ishizawa, Shinji Abe, Hisao Nemoto and Koichiro Tsuchiya : 分岐鎖オリゴグリセロールを用いた難水溶性化合物の物性，薬物動態，薬効の改善, 次世代を担う創薬・医療薬理シンポジウム2014, Aug. 2014.
79.	大塚憲司, Shinji Abe, Masaki Hanibuchi, 木宿昌俊, Kazuyoshi Kawazoe, 加藤幸成 and Yasuhiko Nishioka : 胸膜中皮腫同所移植モデルにおける抗ポドプラニン抗体の抗腫瘍効果, 第18回日本がん分子標的治療学会学術集会, Jun. 2014.
80.	Shinji Abe, 加藤幸成, 金子美華, Mami Azuma, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 悪性胸膜中皮腫同所移植モデルにおける抗ポドプラニン抗体の抗腫瘍効果, 第54回日本呼吸器学会学術講演会, Apr. 2014.
81.	Licht Miyamoto, 渡邊勝志, 田岡千秋, 土橋有希, 松下剛史, Keisuke Ishizawa, Shinji Abe, Hisao Nemoto and Koichiro Tsuchiya : 分岐鎖オリゴグリセロール修飾による疎水性化合物の物性，薬物動態および薬効の改善, 日本薬学会第134年会, Mar. 2014.
82.	土橋有希, Shinji Abe, Licht Miyamoto, 松下剛史, 片桐彩人, Keisuke Ishizawa, Hisao Nemoto and Koichiro Tsuchiya : 新規水溶性Paclitaxelの肺癌に対する抗腫瘍効果の検討, 日本薬学会第134年会, Mar. 2014.
83.	佐藤友香, 小林小春, Mari Nakase, Chiemi Sato, Shinji Abe, Hirofumi Shibata and Mami Azuma : 薬学生の安全意識向上に寄与する教材開発とその有用性, 第134回日本薬学会年会, Mar. 2014.
84.	智子中西, Keisuke Ishizawa, Shinji Abe, Mari Nakase, Hirofumi Shibata, Chiemi Sato, Naokatu Arakaki, Youichi Sato, Naoshi Yamazaki, Jiro Kasahara, Mami Azuma, Tetsuo Yamazaki, Aiko Yamauchi, Yoshiharu Takiguchi and Koichiro Tsuchiya : Study of the method for development of case-problem solving abilities through advanced practice and the results that have been achieved, 日本薬学会第134年会, Mar. 2014.
85.	Shinji Abe, 木宿昌俊, Mari Nakase, Chiemi Sato, Hirofumi Shibata, Kazuyoshi Kawazoe, Mami Azuma, Yasuhiko Nishioka and Kazuo Minakuchi : 悪性胸膜中皮腫移植マウスに対するNZ-1およびラットNK細胞併用投与の抗腫瘍効果, 日本薬学会第134年会, Mar. 2014.
86.	Chiemi Sato, Mari Nakase, Shinji Abe, Hirofumi Shibata and Mami Azuma : 医薬品情報と患者背景の重要性を認識させる事前処方監査トレーニングの実践と検討, 日本薬学会第134回年会, Mar. 2014.
87.	Chiemi Sato, Mari Nakase, Shinji Abe, Hirofumi Shibata and Mami Azuma : 徳島大学薬学部における学生の自己研鑽意識の変化について∼医療の世界で活躍するために∼, 第37回徳島大学薬学部卒後教育公開講座, Nov. 2013.
88.	Shinji Abe, デニスウィリアムズ, Mari Nakase, Chiemi Sato, Hirofumi Shibata, Mami Azuma and Koichiro Tsuchiya : 症例検討能力向上に向けての徳島大学薬学部の取り組み∼米国UNC薬学部とのビデオカンファレンス実施の効果∼, 第52回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
89.	佐藤友香, 小林小春, Mari Nakase, Chiemi Sato, Shinji Abe, Hirofumi Shibata, 溝口徹也, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe, Kazuo Minakuchi and Mami Azuma : 実務実習におけるセーフティマネジメント教材の作成と検討∼薬学実務実習生の調剤ミスをなくすために∼, 第52回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
90.	Mari Nakase, Shinji Abe, Chiemi Sato, Hirofumi Shibata and Mami Azuma : 薬局カウンターでの学生の気付きに基づく課題発見とその成果大学教員訪問を実習成果につなげるために, 第52回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
91.	智子中西, Keisuke Ishizawa, Shinji Abe, Mari Nakase, Hirofumi Shibata, Chiemi Sato, Naokatu Arakaki, Youichi Sato, Naoshi Yamazaki, Jiro Kasahara, Mami Azuma, Tetsuo Yamazaki, Aiko Yamauchi, Yoshiharu Takiguchi and Koichiro Tsuchiya : Study of the method for development of case-problem solving abilities through advanced practice and the results that have been achieved, 第52回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
92.	Chiemi Sato, Mari Nakase, Shinji Abe, Hirofumi Shibata, Koichiro Tsuchiya, Hideji TANAKA and Mami Azuma : 生涯学習の必要性に目覚めさせる徳島大学の取組∼能動学習制度∼, 第52回日本薬学会·日本薬剤師会·日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
93.	Shinji Abe, 加藤幸成, 金子美華, 木宿昌俊, 川添和義, 東満美, Masaki Hanibuchi, 水口和生 and Yasuhiko Nishioka : ヒトNK細胞を介した抗ポドプラニン抗体NZ-8の悪性胸膜中皮腫に対する抗腫瘍効果., 第53回日本呼吸器学会学術講演会, Apr. 2013.
94.	Mari Nakase, Shinji Abe, Hirofumi Shibata and Mami Azuma : 実習生による薬局実務実習情報交換会の実施とその有用性, 日本薬学会第133年会, Mar. 2013.
95.	Shinji Abe, Yuki Taniguchi, Masatoshi Kishuku, Mari Nakase, Hirofumi Shibata, Kazuyoshi Kawazoe, Mami Azuma, Yasuhiko Nishioka and Kazuo Minakuchi : Selectivity of new anti-podoplanin antibody against malignant pleural mesothelioma, 日本薬学会第133年会, Mar. 2013.
96.	Shinji Abe, Yukinari Kato, Mika Kaneko, Jun Huang, Masaki Hanibuchi, Saburo Sone and Yasuhiko Nishioka : 悪性胸膜中皮腫に対するヒトキメラ型抗ポドプラニン抗体療法の検討, 第25回日本バイオセラピィ学会学術集会総会, Dec. 2012.
97.	田島壮一郎, Shinji Abe, Hiroaki Yanagawa, 大和志保, 天羽亜美, 明石晃代, 高井繁美, 宮本登志子, 渡邊美穂, 伏谷秀治, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe, Mami Azuma and Kazuo Minakuchi : 薬学生実務実習における臨床研究・治験教育の導入と評価, 第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
98.	Mari Nakase, Shinji Abe, Hirofumi Shibata and Mami Azuma : 徳島大学薬学部における長期薬局実務実習体制の変遷アンケート結果から考察した問題点とその改善について, 第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
99.	Shinji Abe, 伊勢夏子, 生田賢治, Naoto Okada, Mari Nakase, Hirofumi Shibata, Kazuyoshi Kawazoe, Mami Azuma and Kazuo Minakuchi : 病院実務実習における救急・集中治療領域での徳島大学薬学部教員の取り組み, 第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
100.	Yuki Taniguchi, Shinji Abe, Masatoshi Kishuku, Mami Azuma, Kazuyoshi Kawazoe, Yasuhiko Nishioka and Kazuo Minakuchi : ADCCを介したヒトキメラ型抗ポドプラニン抗体の悪性胸膜中皮腫に対する抗腫瘍効果の検討, 第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
101.	Masaki Hanibuchi, Shinji Abe, Yukinari Kato, Mika Kaneko, Masatoshi Kishuku, Kazuyoshi Kawazoe, Jun Huang, Atsushi Mitsuhashi, Kazuo Minakuchi and Yasuhiko Nishioka : 抗ポドプラニン抗体NZ-1の悪性胸膜中皮腫に対する抗体依存性細胞障害活性と抗腫瘍効果, 第53回日本肺癌学会総会, Nov. 2012.
102.	Mami Azuma, Ryoko Satoyoshi, Shinji Abe and Hirofumi Shibata : 実務実習に臨む学生の意識とその変遷, 第22回日本医療薬学会, Oct. 2012.
103.	Shinji Abe, 伊勢夏子, 生田賢治, Naoto Okada, Ryoko Satoyoshi, Hirofumi Shibata, Kazuyoshi Kawazoe, Mami Azuma and Kazuo Minakuchi : 薬学部教員による救急・集中治療領域における実務実習指導の取り組み, 第22回日本医療薬学会, Oct. 2012.
104.	Ryoko Satoyoshi, Mari Nakase, Shinji Abe, Hirofumi Shibata and Mami Azuma : 実務実習における「問題発見・解決記録」の導入と分析, 第45回日本薬剤師会学術大会, Oct. 2012.
105.	Yasuhiko Nishioka, Shinji Abe, Masatoshi Kishuku, Kazuyoshi Kawazoe, Jun Huang, Masaki Hanibuchi, Kazuo Minakuchi, Saburo Sone and Yukinari Kato : 悪性胸膜中皮腫に対するラット-ヒトキメラ型抗ポドプラニン抗体NZ-8の抗腫瘍効果, 第71回日本癌学会学術総会, Sep. 2012.
106.	Kato Yukinari, Shinji Abe, Kazuo Minakuchi and Yasuhiko Nishioka : ヒトキメラ型抗ポドプラニン抗体による転移抑制機序の解明, 第16回日本がん分子標的治療学会学術集会, Jun. 2012.
107.	Yasuhiko Nishioka, Shinji Abe, Yukinari Kato, Masatoshi Kishuku, Kazuyoshi Kawazoe, Jun Huang, Masaki Hanibuchi, Kazuo Minakuchi and Saburo Sone : 悪性胸膜中皮腫に対するヒトキメラ型抗ポドプラニン抗体NZ-8の抗腫瘍効果, 第16回日本がん分子標的治療学会学術集会, Jun. 2012.
108.	Shinji Abe, Yukinari Kato, Mika Kaneko, Masatoshi Kisyuku, Kazuyoshi Kawazoe, Mami Azuma, Kazuo Minakuchi, Saburo Sone and Yasuhiko Nishioka : 悪性胸膜中皮腫に対する抗ポドプラニン抗体NZ-1の抗腫瘍効果に関する検討, 第52回日本呼吸器学会学術講演会, Apr. 2012.
109.	Jun Huang, Shinji Abe, Yuki Morita, Shuji Ozaki, Masatoshi Kishuku, Kazuo Minakuchi, Masaki Hanibuchi, Toshio Matsumoto, Saburo Sone and Yasuhiko Nishioka : Antibody-dependent cellular cytotoxicity against mesothelioma cells mediated by anti-HM 1.24 antibodies, 第52回日本呼吸器学会学術講演会, Apr. 2012.
110.	Ryoko Satoyoshi, Shinji Abe and Mami Azuma : 徳島大学における薬局実習への取り組み -実習薬局での学生の患者応対能力向上を目指して-, 日本薬学会第132年会, Mar. 2012.
111.	Mami Azuma, Mayumi Sugimura, Shinji Abe and Ryoko Satoyoshi : 長期薬局実務実習における実習環境についての一考察, 日本薬学会第132年会, Mar. 2012.
112.	Shinji Abe, Yuki Taniguchi, Masatoshi Kishuku, Ryoko Satoyoshi, Kazuyoshi Kawazoe, Mami Azuma, Yasuhiko Nishioka and Kazuo Minakuchi : Expression of the new tumor antigen OFA-iLRP in lung cancer, 日本薬学会第132年会, Mar. 2012.
113.	Ryoko Satoyoshi, Shinji Abe and Mami Azuma : 実務家教員によるSP(模擬患者)訪問の有用性評価, 第33回徳島大学薬学部卒後教育公開講座, Dec. 2011.
114.	Mami Azuma, Mayumi Sugimura, Chieko Okumura, Shinji Abe and Ryoko Satoyoshi : 徳島大学薬学部新制度実務実習の体制と成果, 第33回徳島大学薬学部卒後教育公開講座, Dec. 2011.
115.	Shinji Abe, 加藤幸成, 金子美華, 黄俊, Masaki Hanibuchi, Saburo Sone and Yasuhiko Nishioka : 悪性胸膜中皮腫に対する抗ポドプラニン抗体療法の検討, 第24回日本バイオセラピィ学会学術集会総会, Dec. 2011.
116.	Yuya Horinouchi, 中村敏己, Takumi Sakurada, 森剛志, Ken Konaka, 三木幸代, 田島壮一郎, Shinji Abe, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe and Kazuo Minakuchi : ベバシズマブ投与大腸がん患者における早期高血圧の効果予測因子としての意義, 第50回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2011.
117.	Shinji Abe, Yuki Taniguchi, Masatoshi Kishuku, 加藤幸成, Kazuyoshi Kawazoe, Mami Azuma, Yasuhiko Nishioka and Kazuo Minakuchi : ポドプラニンを標的とした悪性胸膜中皮腫に対する新規抗体療法の検討, 第50回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2011.
118.	Ryoko Satoyoshi, Shinji Abe and Mami Azuma : 実務家教員によるSP(模擬患者)訪問の有用性評価 -学外実習施設指導薬剤師との連携と学生の学習意欲向上に向けて-, 第50回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2011.
119.	Mami Azuma, Mayumi Sugimura, Chieko Okumura, Shinji Abe and Ryoko Satoyoshi : 学生の意識変化にみる実務実習の効果, 第50回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2011.
120.	玉川晋也, 八塚研治, Shinji Abe, Hitoshi Kubo, Koichiro Tsuchiya, Masafumi Harada and Hisao Nemoto : The new development of MRI contrast medium, 第37回反応と合成の進歩シンポジウム, Nov. 2011.
121.	Shinji Abe, Dennis Williams, Mami Azuma, Koichiro Tsuchiya, 美妃山下, 麻衣子町田 and Hiroshi Kiwada : 日米の薬学部学生間におけるビデオ会議システムを用いた症例検討カンファレンス実施の試み, 日本医療薬学会第21回年会, Oct. 2011.
122.	Mami Azuma, Mayumi Sugimura, Chieko Okumura, Shinji Abe and Hiroshi Kiwada : 徳島大学薬学部長期薬局実務実習初年度連携指導体制の検証と課題, 第21回日本医療薬学会年会, Oct. 2011.
123.	加藤幸成, Yasuhiko Nishioka, Shinji Abe, 水口和夫 and Saburo Sone : 悪性グリオーマに対する抗ポドプラニン抗体NZ-1の活性評価, 第15回日本がん分子標的治療学会学術集会, Jun. 2011.
124.	Yasuhiko Nishioka, Shinji Abe, 加藤幸成, 木宿昌俊, Kazuyoshi Kawazoe, 黄俊, Masaki Hanibuchi, 水口和夫 and Saburo Sone : 抗ポドプラニン抗体NZ-1の悪性胸膜中皮腫に対する抗体依存性細胞障害活性と抗腫瘍効果, 第15回日本がん分子標的治療学会学術集会, Jun. 2011.
125.	Shinji Abe, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe and Kazuo Minakuchi : 徳島大学病院における病院実務実習カリキュラムとその成果, 日本薬学会第131年会, Mar. 2011.
126.	Chieko Okumura, Mayumi Sugimura, Shinji Abe, 米田良子, 上村卓広, 溝口徹也, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe, Kazuo Minakuchi, Mami Azuma and Yoshihisa Takaishi : 「病院実務実習」における指導薬剤師と薬学部実務家教員の連携, 第31回徳島大学薬学部卒後教育公開講座, Dec. 2010.
127.	Keisuke Ishizawa, 中西智子, Hirofumi Shibata, Shinji Abe, Mayumi Sugimura, Chieko Okumura, Yoshiyuki Yoshimura, Youichi Sato, Naokatu Arakaki, Kazuyoshi Kawazoe, Mami Azuma, Koichiro Tsuchiya, Aiko Yamauchi, Tetsuo Yamazaki and Kazuo Minakuchi : 徳島大学における薬学部・薬剤部連携による病院実務実習の実践, 第20回日本医療薬学会年会, Nov. 2010.
128.	西迫寛隆, 米田良子, 上村卓広, 溝口徹也, Shinji Abe, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe and Kazuo Minakuchi : 徳島大学病院におけるオピオイド製剤使用状況調査と適正使用における薬剤師の働き, 第20回日本医療薬学会年会, Nov. 2010.
129.	Yuya Horinouchi, 櫻田巧, 中村敏己, 森剛志, 小中健, 三木幸代, 田島壮一郎, 西迫寛隆, Shinji Abe, Kazuyoshi Kawazoe and Kazuo Minakuchi : 血圧上昇を指標としたベバシツマブ投与結腸・直腸がん患者の効果予測に関する検討, 第20回日本医療薬学会年会, Nov. 2010.
130.	渡邉美穂, Hirofumi Shibata, 上松卓, 伏谷秀治, Shinji Abe, Kazuyoshi Kawazoe, Tetsuo Yamazaki and Kazuo Minakuchi : 病院施設のATP拭き取り検査と細菌汚染状況調査, 第49回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2010.
131.	Yuya Horinouchi, 櫻田巧, 中村敏己, Tsuyoshi Mori, 小中健, 三木幸代, 田島壮一郎, 西迫寛隆, Shinji Abe, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe and Kazuo Minakuchi : 分子標的治療薬ベバシズマブによる血圧上昇について ∼発現状況調査ならびに効果予測の検討∼, 第49回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2010.
132.	太田佳那, Youichi Sato, 岡本茉佑子, Shinji Abe, ASHRAF ABDEL AZIM EWIS, Masako Sei, Kazuyoshi Kawazoe and Kazuo Minakuchi : 五味子水抽出物の新規作用に関する検討, 第49回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2010.
133.	大上知妃呂, 佐原理沙, 田島壮一郎, Shinji Abe, Kazuyoshi Kawazoe and Kazuo Minakuchi : ヒト腸管上皮細胞における薬物代謝酵素CYP3A4 に対する生薬の影響, 第49回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2010.
134.	木宿昌俊, Shinji Abe, 森田結貴, Kazuhiko Teraoka, 久次米敏秀, Yasuhiko Nishioka, Kazuyoshi Kawazoe, Saburo Sone and Kazuo Minakuchi : 成熟樹状細胞由来sVEGFR-1 の腫瘍血管新生に及ぼす影響, 第49回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2010.
135.	森田結貴, Shinji Abe, 木宿昌俊, Yasuhiko Nishioka, Kazuyoshi Kawazoe, Saburo Sone and Kazuo Minakuchi : HM1.24 を標的とした悪性胸膜中皮腫に対する抗体療法の開発, 第49回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2010.
136.	富永えりか, Keisuke Ishizawa, Masaki Imanishi, 櫻田巧, 谷口順平, 藤井聖子, Yuya Horinouchi, Yoshitaka Kihira, Shinji Abe, Kazuyoshi Kawazoe, Koichiro Tsuchiya, Toshiaki Tamaki and Kazuo Minakuchi : アンジオテンシンII による血管リモデリングに対するニトロソニフェジピンの影響, 第49回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2010.
137.	下岡幸恵, 生田賢治, 伊勢夏子, Shinji Abe, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe and Kazuo Minakuchi : 集学治療病棟専任薬剤師によるテイコプラニン処方設計へのリアルタイム血中濃度測定を介した薬学的支援, 第4回日本腎と薬剤研究会学術大会2010, Oct. 2010.
138.	Keisuke Ishizawa, Kazuyoshi Kawazoe, Mami Azuma, Koichiro Tsuchiya, Aiko Yamauchi, Tetsuo Yamazaki, Kazuo Minakuchi, 智子中西, Hirofumi Shibata, Shinji Abe, Mayumi Sugimura, Chieko Okumura, Yoshiyuki Yoshimura, Youichi Sato and Naokatu Arakaki : P1-571 徳島大学における薬学部・薬剤部連携による病院実務実習の実践(一般演題ポスター発表,薬学教育(実務実習),臨床から学び臨床へと還元する医療薬学), The Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences, Vol.20, No.0, 382, 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390845713041900800 (CiNii: 1390845713041900800)
139.	森剛志, 西迫寛隆, 中村敏己, 三木幸代, Yuya Horinouchi, 櫻田巧, Shinji Abe, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe and Kazuo Minakuchi : 外来乳がん化学療法におけるクラスター解析を用いた副作用予測の試み, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
140.	Shinji Abe, Yasuhiko Nishioka, 木宿昌俊, 中野沙織, 森田結貴, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe, Saburo Sone and Kazuo Minakuchi : 特異的癌抗原MAGE-3を標的とした癌免疫療法の検討, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
141.	真部裕一, Kazuyoshi Kawazoe, Shinji Abe, Kazuo Minakuchi, 安藝健作 and Eiji Hosoi : バルプロ酸ナトリウムによる血小板凝集抑制メカニズムについての検討, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
142.	下岡幸恵, 生田賢治, 上村卓広, Shinji Abe, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe and Kazuo Minakuchi : 集学治療病棟専任薬剤師による薬剤管理業務, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
143.	腰岡桜, Youichi Sato, 桐野靖, 紙本尚幸, Shinji Abe, Kazuyoshi Kawazoe, Yutaka Nakahori and Kazuo Minakuchi : DPP4欠損ラットを用いた1型糖尿病誘発モデルにおける脂質代謝異常発症のメカニズム解明, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
144.	阿部有里子, 宮谷綾, 西迫寛隆, Shinji Abe, Kazuyoshi Kawazoe and Kazuo Minakuchi : ウシ副腎髄質クロマフィン細胞の漢方薬成分に対する応答, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
145.	平松由佳子, 阿古目健志, Shinji Abe, Kazuyoshi Kawazoe, Junji Terao and Kazuo Minakuchi : 漢方薬の品質変化と剤型との関連性, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
146.	中野沙織, Shinji Abe, 森田結貴, 木宿昌俊, Yasuhiko Nishioka, Kazuyoshi Kawazoe, Saburo Sone and Kazuo Minakuchi : 新規癌抗原OFA-iLRPを標的とした肺癌に対する免疫療法の開発, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
147.	東谷香奈, 大上知妃呂, 野口悠高, Shinji Abe, Kazuyoshi Kawazoe and Kazuo Minakuchi : Caco-2細胞に発現したCYP3A4に及ぼす生薬抽出物の影響, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
148.	伏谷秀治, Hirofumi Shibata, 柴田高洋, Kazuyoshi Kawazoe, 安倍正博, Shinji Abe, Tomihiko Higuti, 庄野文章 and Kazuo Minakuchi : 徳島大学病院病棟における環境中の浮遊真菌調査について, 第24回日本環境感染学会総会, Feb. 2009.
149.	河野渉, 引地香織, Hirofumi Shibata, Shinji Abe, Kazuyoshi Kawazoe, Kazuo Minakuchi and Tomihiko Higuti : 銀翹散のin vitro抗インフルエンザウイルス活性につて, 第47回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 97, Nov. 2008.
150.	白石泰郎, 西迫寛隆, Toshitaka Ikehara, Shinji Abe, Kazuyoshi Kawazoe and Kazuo Minakuchi : ウシ副腎髄質クロマフィン細胞におけるアクチンと細胞容積調節機能に及ぼす変動磁界の影響, 第47回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 84, Nov. 2008.
151.	紙本尚幸, 桐野靖, 腰岡桜, Youichi Sato, Shinji Abe, Kazuyoshi Kawazoe, Kazuo Minakuchi and Yutaka Nakahori : ストレプトゾトシン誘発糖尿病ラットモデルにおけるDipptidyl pdptidase 4と脂質代謝異常の関連性について, 第47回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 83, Nov. 2008.
152.	河野渉, 引地香織, Hirofumi Shibata, Shinji Abe, 川添和義, 水口和生 and Tomihiko Higuti : 銀翹散のin vitro抗インフルエンザウイルス活性について, 第47回日本薬学会・日本病院薬剤師会中国四国支部学術大会, Nov. 2008.
153.	道倉亜実, Shinji Abe, 沼田ちえ, 田中麻衣, Miwa Bando, Eiji Hosoi, Kazuyoshi Kawazoe, Hitoshi Houchi and Kazuo Minakuchi : ヒト血小板機能に及ぼす抗てんかん剤の影響, 第46回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 158, Nov. 2007.
154.	Shinji Abe, 木宿昌俊, Yasuhiko Nishioka, 中村敏己, 西迫寛隆, Kazuhiko Teraoka, 久次米敏秀, Kazuyoshi Kawazoe, Saburo Sone and Kazuo Minakuchi : 肺癌に対する腫瘍特異的免疫療法の検討, 第46回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 148, Nov. 2007.
155.	下岡幸恵, 鳥井真由美, 伏谷秀治, Harutaka Yamaguchi, Shinji Abe, Kazuyoshi Kawazoe, Masaji Nishimura and Kazuo Minakuchi : 腎機能障害患者におけるテイコプラニン連日投与方法に関する検討, The Japanese Journal of Therapeutic Drug Monitoring, Vol.24, No.3, s123, Jul. 2007.
156.	Shinji Abe, 久次米敏秀, 寺岡和彦, Kazuyoshi Kawazoe and Kazuo Minakuchi : 米国における薬剤師育成の現状, 第45回日本薬学会・日本病院薬剤師会中国四国支部学術大会, 204, Oct. 2006.
157.	白潟朋美, 道倉亜実, Shinji Abe, 沼田ちえ, 杉豪介, 田中麻衣, Miwa Bando, Eiji Hosoi, Kazuyoshi Kawazoe, Hitoshi Houchi and Kazuo Minakuchi : ヒト活性化血小板における抗血小板薬の効果, 第45回日本薬学会・日本病院薬剤師会中国四国支部学術大会, 138, Oct. 2006.
158.	黒川ふみ, Shinji Abe, 鳥井真由美, 濱野修一, Kazuyoshi Kawazoe, Hitoshi Houchi and Kazuo Minakuchi : アスピリンとNSAIDs併用における相互作用 ∼ヒト血小板凝集能に及ぼす影響∼, 第45回日本薬学会・日本病院薬剤師会中国四国支部学術大会, 138, Oct. 2006.
159.	松村敏彦, 宮本由加里, 黒川ふみ, Shinji Abe, 榊原啓之, Keisuke Ishizawa, Koichiro Tsuchiya, 清水寛, Junji Terao, Toshiaki Tamaki, Kazuyoshi Kawazoe and Kazuo Minakuchi : ラット強制水泳試験における漢方薬の抗うつ作用の検討, 第45回日本薬学会・日本病院薬剤師会中国四国支部学術大会, 125, Oct. 2006.
160.	南有紀, 塩田直青子, Toshitaka Ikehara, 庄野正行, Keisuke Ishizawa, Kazuo Yoshizaki, Yohsuke Kinouchi, Shinji Abe, Hitoshi Houchi, Kazuyoshi Kawazoe and Kazuo Minakuchi : ウシ副腎髄質細胞の容積変化に及ぼす変動磁界の影響, 第45回日本薬学会・日本病院薬剤師会中国四国支部学術大会, 76, Oct. 2006.
161.	白潟朋美, 道倉亜実, Shinji Abe, 沼谷ちえ, 杉豪介, 田中麻衣, 坂東美和, Eiji Hosoi, Hitoshi Houchi, Kazuyoshi Kawazoe and Kazuo Minakuchi : ヒト活性化血小板における抗血小板薬の効果, 日本薬学会・日本病院薬剤師会第45回中国四国支部学術大会, Oct. 2006.
162.	西迫寛隆, Keisuke Ishizawa, 溝口徹也, 桐野靖, Shinji Abe, Kazuyoshi Kawazoe and Kazuo Minakuchi : 結核病棟薬剤管理指導におけるワークシートの活用とNSTとの連携, 第44回日本薬学会・日本病院薬剤師会中国四国支部学術大会, 190, Nov. 2005.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

腫瘍特異的抗体療法におけるADCC活性誘導機構の解明と新規抗体医薬開発への応用 (Project/Area Number: 23K06256 )
Investigation of effective and safe cancer specific antibody therapy against malignant pleural mesothelioma (Project/Area Number: 20K07197 )
Investigation of control factors in tumor specific antibody therapy mediated by ADCC (Project/Area Number: 16K08372 )
Development of a novel targeting therapy using anti-podoplanin antibody against malignant pleural mesothelioma (Project/Area Number: 25460189 )
Establishment of novel immunotherapy against malignant mesothelioma (Project/Area Number: 23790185 )
Investigation of OFA-iLRP targeted cancer immunother apy against lung cancer (Project/Area Number: 20790136 )
Search by Researcher Number (00403717)

Professor : Abe, Shinji

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)